☰

Xandra Owens Breakefield - Publications

Affiliations: 
Harvard Medical School/ MGH, Boston, MA, United States 
Area:
Neurogenetics, Gene Therapy
Website:
http://www.massgeneral.org/breakefieldlab/
Tree Info Grants Similar researchers PubMed Report error

265/500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Maalouf KE, Vaine CA, Frederick DM, Yoshinaga A, Obuchi W, Mahjoum S, Nieland L, Al Ali J, Bragg DC, Breakefield XO, Breyne K. Tracking human neurologic disease status in mouse brain/plasma using reporter-tagged, EV-associated biomarkers. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 37198883 DOI: 10.1016/j.ymthe.2023.05.011  0.597
2022 Prabhakar S, Beauchamp RL, Cheah PS, Yoshinaga A, Haidar EA, Lule S, Mani G, Maalouf K, Stemmer-Rachamimov A, Jung DH, Welling DB, Giovannini M, Plotkin SR, Maguire CA, Ramesh V, ... Breakefield XO, et al. Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Molecular Therapy. Methods & Clinical Development. 26: 169-180. PMID 35846573 DOI: 10.1016/j.omtm.2022.06.012  0.649
2021 Cheah PS, Prabhakar S, Yellen D, Beauchamp RL, Zhang X, Kasamatsu S, Bronson RT, Thiele EA, Kwiatkowski DJ, Stemmer-Rachamimov A, György B, Ling KH, Kaneki M, Tannous BA, Ramesh V, ... ... Breakefield XO, et al. Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Science Advances. 7. PMID 33523984 DOI: 10.1126/sciadv.abb1703  0.632
2020 Al Ali J, Vaine CA, Shah S, Campion L, Hakoum A, Supnet ML, Acuña P, Aldykiewicz G, Multhaupt-Buell T, Ganza NGM, Lagarde JBB, De Guzman JK, Go C, Currall B, Trombetta B, ... ... Breakefield XO, et al. TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-Linked Dystonia-Parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 32975318 DOI: 10.1002/mds.28305  0.552
2020 Abels ER, Maas SLN, Tai E, Ting DT, Broekman MLD, Breakefield XO, El Khoury J. GlioM&M: Web-based tool for studying circulating and infiltrating monocytes and macrophages in glioma. Scientific Reports. 10: 9898. PMID 32555306 DOI: 10.1038/s41598-020-66728-w  0.313
2020 Cruz L, György B, Cheah PS, Kleinstiver BP, Eimer WA, Garcia SP, Sharma N, Ozelius LJ, Bragg DC, Joung JK, Norberto de Souza O, Macedo Timmers LFS, Breakefield XO. Mutant Allele-Specific CRISPR Disruption in DYT1 Dystonia Fibroblasts Restores Cell Function. Molecular Therapy. Nucleic Acids. 21: 1-12. PMID 32502938 DOI: 10.1016/J.Omtn.2020.05.009  0.624
2020 O'Brien K, Breyne K, Ughetto S, Laurent LC, Breakefield XO. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nature Reviews. Molecular Cell Biology. PMID 32457507 DOI: 10.1038/s41580-020-0251-y  0.331
2020 Maas SLN, Abels ER, Van De Haar LL, Zhang X, Morsett L, Sil S, Guedes J, Sen P, Prabhakar S, Hickman SE, Lai CP, Ting DT, Breakefield XO, Broekman MLD, El Khoury J. Glioblastoma hijacks microglial gene expression to support tumor growth. Journal of Neuroinflammation. 17: 120. PMID 32299465 DOI: 10.1186/s12974-020-01797-2  0.359
2020 Lucero R, Zappulli V, Sammarco A, Murillo OD, Cheah PS, Srinivasan S, Tai E, Ting DT, Wei Z, Roth ME, Laurent LC, Krichevsky AM, Breakefield XO, Milosavljevic A. Glioma-Derived miRNA-Containing Extracellular Vesicles Induce Angiogenesis by Reprogramming Brain Endothelial Cells. Cell Reports. 30: 2065-2074.e4. PMID 32075753 DOI: 10.1016/j.celrep.2020.01.073  0.325
2020 Yekula A, Minciacchi VR, Morello M, Shao H, Park Y, Zhang X, Muralidharan K, Freeman MR, Weissleder R, Lee H, Carter B, Breakefield XO, Di Vizio D, Balaj L. Large and small extracellular vesicles released by glioma cells and . Journal of Extracellular Vesicles. 9: 1689784. PMID 31839905 DOI: 10.1080/20013078.2019.1689784  0.329
2019 Candelario KM, Balaj L, Zheng T, Skog J, Scheffler B, Breakefield X, Schüle B, Steindler DA. Exosome/Microvesicle Content is Altered in LRRK2 Mutant iPSC-derived Neural Cells. The Journal of Comparative Neurology. PMID 31743443 DOI: 10.1002/Cne.24819  0.356
2019 Hanlon KS, Kleinstiver BP, Garcia SP, Zaborowski MP, Volak A, Spirig SE, Muller A, Sousa AA, Tsai SQ, Bengtsson NE, Lööv C, Ingelsson M, Chamberlain JS, Corey DP, Aryee MJ, ... ... Breakefield XO, et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nature Communications. 10: 4439. PMID 31570731 DOI: 10.1038/S41467-019-12449-2  0.629
2019 Prabhakar S, Cheah PS, Zhang X, Zinter M, Gianatasio M, Hudry E, Bronson RT, Kwiatkowski DJ, Stemmer-Rachamimov A, Maguire CA, Sena-Esteves M, Tannous BA, Breakefield XO. Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Molecular Therapy. Methods & Clinical Development. 15: 18-26. PMID 31534984 DOI: 10.1016/J.Ibror.2019.07.1575  0.659
2019 Abels ER, Maas SLN, Nieland L, Wei Z, Cheah PS, Tai E, Kolsteeg CJ, Dusoswa SA, Ting DT, Hickman S, El Khoury J, Krichevsky AM, Broekman MLD, Breakefield XO. Glioblastoma-Associated Microglia Reprogramming Is Mediated by Functional Transfer of Extracellular miR-21. Cell Reports. 28: 3105-3119.e7. PMID 31533034 DOI: 10.1016/j.celrep.2019.08.036  0.332
2019 Wiklander OPB, Brennan MÁ, Lötvall J, Breakefield XO, El Andaloussi S. Advances in therapeutic applications of extracellular vesicles. Science Translational Medicine. 11. PMID 31092696 DOI: 10.1126/scitranslmed.aav8521  0.302
2019 Ricklefs FL, Maire CL, Reimer R, Dührsen L, Kolbe K, Holz M, Schneider E, Rissiek A, Babayan A, Hille C, Pantel K, Krasemann S, Glatzel M, Heiland DH, Flitsch J, ... ... Breakefield XO, et al. Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. Journal of Extracellular Vesicles. 8: 1588555. PMID 30949309 DOI: 10.1080/20013078.2019.1588555  0.302
2019 Zaborowski MP, Lee K, Na YJ, Sammarco A, Zhang X, Iwanicki M, Cheah PS, Lin HY, Zinter M, Chou CY, Fulci G, Tannous BA, Lai CP, Birrer MJ, Weissleder R, ... ... Breakefield XO, et al. Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. Cell Reports. 27: 255-268.e6. PMID 30943406 DOI: 10.1016/J.Celrep.2019.03.003  0.327
2018 Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO. Multidimensional communication in the microenvirons of glioblastoma. Nature Reviews. Neurology. PMID 29985475 DOI: 10.1038/s41582-018-0025-8  0.311
2018 György B, Lööv C, Zaborowski MP, Takeda S, Kleinstiver BP, Commins C, Kastanenka K, Mu D, Volak A, Giedraitis V, Lannfelt L, Maguire CA, Joung JK, Hyman BT, Breakefield XO, et al. CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. Molecular Therapy. Nucleic Acids. 11: 429-440. PMID 29858078 DOI: 10.1016/J.Omtn.2018.03.007  0.634
2018 Aneichyk T, Hendriks WT, Yadav R, Shin D, Gao D, Vaine CA, Collins RL, Domingo A, Currall B, Stortchevoi A, Multhaupt-Buell T, Penney EB, Cruz L, Dhakal J, Brand H, ... ... Breakefield XO, et al. Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly. Cell. 172: 897-909.e21. PMID 29474918 DOI: 10.1016/J.Cell.2018.02.011  0.616
2018 György B, Cruz L, Yellen D, Aufiero M, Alland I, Zhang X, Ericsson M, Fraefel C, Li YC, Takeda S, Hyman BT, Breakefield XO. Mutant torsinA in the heterozygous DYT1 state compromises HSV propagation in infected neurons and fibroblasts. Scientific Reports. 8: 2324. PMID 29396398 DOI: 10.1038/S41598-018-19865-2  0.36
2018 Reátegui E, van der Vos KE, Lai CP, Zeinali M, Atai NA, Aldikacti B, Floyd FP, H Khankhel A, Thapar V, Hochberg FH, Sequist LV, Nahed BV, S Carter B, Toner M, Balaj L, ... ... Breakefield XO, et al. Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nature Communications. 9: 175. PMID 29330365 DOI: 10.1038/S41467-017-02261-1  0.317
2018 Lee K, Fraser K, Ghaddar B, Yang K, Kim E, Balaj L, Chiocca EA, Breakefield XO, Lee H, Weissleder R. Multiplexed Profiling of Single Extracellular Vesicles. Acs Nano. PMID 29286635 DOI: 10.1021/Acsnano.7B07060  0.306
2017 Bragg DC, Mangkalaphiban K, Vaine CA, Kulkarni NJ, Shin D, Yadav R, Dhakal J, Ton ML, Cheng A, Russo CT, Ang M, Acuña P, Go C, Franceour TN, Multhaupt-Buell T, ... ... Breakefield XO, et al. Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1. Proceedings of the National Academy of Sciences of the United States of America. PMID 29229810 DOI: 10.1073/Pnas.1712526114  0.604
2017 György B, Sage C, Indzhykulian AA, Scheffer DI, Brisson AR, Tan S, Wu X, Volak A, Mu D, Tamvakologos PI, Li Y, Fitzpatrick Z, Ericsson M, Breakefield XO, Corey DP, et al. Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome-Associated AAV. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28082074 DOI: 10.1016/J.Ymthe.2016.12.010  0.66
2016 Maas SL, Breakefield XO, Weaver AM. Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends in Cell Biology. PMID 27979573 DOI: 10.1016/J.Tcb.2016.11.003  0.301
2016 Zappulli V, Friis KP, Fitzpatrick Z, Maguire CA, Breakefield XO. Extracellular vesicles and intercellular communication within the nervous system. The Journal of Clinical Investigation. 126: 1198-207. PMID 27035811 DOI: 10.1172/Jci81134  0.62
2016 Hall J, Prabhakar S, Balaj L, Lai CP, Cerione RA, Breakefield XO. Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma. Cellular and Molecular Neurobiology. PMID 27017608 DOI: 10.1007/S10571-015-0309-0  0.365
2016 Zhang X, Abels ER, Redzic JS, Margulis J, Finkbeiner S, Breakefield XO. Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture. Cellular and Molecular Neurobiology. PMID 26951563 DOI: 10.1007/S10571-016-0350-7  0.364
2016 Choudhury SR, Hudry E, Maguire CA, Sena-Esteves M, Breakefield XO, Grandi P. Viral vectors for therapy of neurologic diseases. Neuropharmacology. PMID 26905292 DOI: 10.1016/J.Neuropharm.2016.02.013  0.639
2016 Ito N, Hendriks WT, Dhakal J, Vaine CA, Liu C, Shin D, Shin K, Wakabayashi-Ito N, Dy M, Multhaupt-Buell T, Sharma N, Breakefield XO, Bragg DC. Decreased N-TAF1 expression in X-Linked Dystonia-Parkinsonism patient-specific neural stem cells. Disease Models & Mechanisms. PMID 26769797 DOI: 10.1242/Dmm.022590  0.638
2016 Gyorgy B, Ingelsson M, Loov C, Takeda S, Lannfelt L, Hyman BT, Breakefield XO. 567. CRISPR-Cas9 Mediated Gene Editing in a Monogenic Form of Alzheimer's Disease Molecular Therapy. 24: S226-S227. DOI: 10.1016/S1525-0016(16)33375-5  0.328
2015 Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study. Bioscience. 65: 783-797. PMID 26955082 DOI: 10.1093/biosci/biv084  0.325
2015 Prabhakar S, Zhang X, Goto J, Han S, Lai C, Bronson R, Sena-Esteves M, Ramesh V, Stemmer-Rachamimov A, Kwiatkowski DJ, Breakefield XO. Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. Neurobiology of Disease. 82: 22-31. PMID 26019056 DOI: 10.1016/J.Nbd.2015.04.018  0.384
2015 Balaj L, Atai NA, Chen W, Mu D, Tannous BA, Breakefield XO, Skog J, Maguire CA. Heparin affinity purification of extracellular vesicles. Scientific Reports. 5: 10266. PMID 25988257 DOI: 10.1038/Srep10266  0.624
2015 Lai CP, Kim EY, Badr CE, Weissleder R, Mempel TR, Tannous BA, Breakefield XO. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nature Communications. 6: 7029. PMID 25967391 DOI: 10.1038/Ncomms8029  0.317
2015 Wakabayashi-Ito N, Ajjuri RR, Henderson BW, Doherty OM, Breakefield XO, O'Donnell JM, Ito N. Mutant human torsinA, responsible for early-onset dystonia, dominantly suppresses GTPCH expression, dopamine levels and locomotion in Drosophila melanogaster. Biology Open. 4: 585-95. PMID 25887123 DOI: 10.1242/bio.201411080  0.367
2015 Gong Y, Mu D, Prabhakar S, Moser A, Musolino P, Ren J, Breakefield XO, Maguire CA, Eichler FS. Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 824-34. PMID 25592337 DOI: 10.1038/Mt.2015.6  0.672
2015 Ahmed SG, Hadaegh F, Sena-Esteves M, Maguire CA, Fulci G, Breakefield XO, Brenner GJ. 635. Mechanisms of Caspase-1 Mediated Schwannoma Regression Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34244-7  0.657
2015 Prabhakar S, Zhang X, Goto J, Sena-Esteves M, Ramesh V, Bronson R, Chen JW, Stemmer-Rachamimov AO, Kwiatkowski DJ, Breakefield XO. 196. AAV-Mediated Gene Replacement Therapy in Mouse Model of Tuberous Sclerosis Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)33801-1  0.4
2015 Gyorgy B, Sage C, Scheffer D, Indzhykulian AA, Mu D, Breakefield XO, Maguire CA, Corey DP. 16. Exosome-Associated AAV as a Novel Platform for Gene Therapy of Hearing Loss Molecular Therapy. 23: S7. DOI: 10.1016/S1525-0016(16)33620-6  0.655
2014 Rajendran L, Bali J, Barr MM, Court FA, Krämer-Albers EM, Picou F, Raposo G, van der Vos KE, van Niel G, Wang J, Breakefield XO. Emerging roles of extracellular vesicles in the nervous system. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 15482-9. PMID 25392515 DOI: 10.1523/Jneurosci.3258-14.2014  0.327
2014 Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, et al. Update from the 2013 International Neurofibromatosis Conference. American Journal of Medical Genetics. Part A. 164: 2969-78. PMID 25255738 DOI: 10.1002/Ajmg.A.36754  0.303
2014 Maguire CA, Ramirez SH, Merkel SF, Sena-Esteves M, Breakefield XO. Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 817-39. PMID 25159276 DOI: 10.1007/S13311-014-0299-5  0.661
2014 Hettich J, Ryan SD, de Souza ON, Saraiva Macedo Timmers LF, Tsai S, Atai NA, da Hora CC, Zhang X, Kothary R, Snapp E, Ericsson M, Grundmann K, Breakefield XO, Nery FC. Biochemical and cellular analysis of human variants of the DYT1 dystonia protein, TorsinA/TOR1A. Human Mutation. 35: 1101-13. PMID 24930953 DOI: 10.1002/Humu.22602  0.317
2014 Vader P, Breakefield XO, Wood MJ. Extracellular vesicles: emerging targets for cancer therapy. Trends in Molecular Medicine. 20: 385-93. PMID 24703619 DOI: 10.1016/j.molmed.2014.03.002  0.306
2014 Lai CP, Mardini O, Ericsson M, Prabhakar S, Maguire CA, Chen JW, Tannous BA, Breakefield XO. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. Acs Nano. 8: 483-94. PMID 24383518 DOI: 10.1021/Nn404945R  0.628
2014 Lai CP, Tannous BA, Breakefield XO. Noninvasive in vivo monitoring of extracellular vesicles. Methods in Molecular Biology (Clifton, N.J.). 1098: 249-58. PMID 24166382 DOI: 10.1007/978-1-62703-718-1_19  0.308
2013 Armata IA, Balaj L, Kuster JK, Zhang X, Tsai S, Armatas AA, Multhaupt-Buell TJ, Soberman R, Breakefield XO, Ichinose H, Sharma N. Dopa-responsive dystonia: functional analysis of single nucleotide substitutions within the 5' untranslated GCH1 region. Plos One. 8: e76975. PMID 24124602 DOI: 10.1371/Journal.Pone.0076975  0.322
2013 Atai NA, Balaj L, van Veen H, Breakefield XO, Jarzyna PA, Van Noorden CJ, Skog J, Maguire CA. Heparin blocks transfer of extracellular vesicles between donor and recipient cells. Journal of Neuro-Oncology. 115: 343-51. PMID 24002181 DOI: 10.1007/S11060-013-1235-Y  0.625
2013 Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, Loguidice L, Soto H, Garrett M, Zhu LD, Sivaraman S, Chen C, Wong ET, Carter BS, Hochberg FH, ... Breakefield XO, et al. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Molecular Therapy. Nucleic Acids. 2: e109. PMID 23881452 DOI: 10.1038/Mtna.2013.28  0.618
2013 Prabhakar S, Goto J, Zhang X, Zuang X, Sena-Esteves M, Bronson R, Brockmann J, Gianni D, Wojtkiewicz GR, Chen JW, Stemmer-Rachamimov A, Kwiatkowski DJ, Breakefield XO. Stochastic model of Tsc1 lesions in mouse brain. Plos One. 8: e64224. PMID 23696872 DOI: 10.1371/Journal.Pone.0064224  0.343
2013 Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, et al. Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 266-8. PMID 23369965 DOI: 10.1038/Mt.2013.4  0.333
2013 Prabhakar S, Taherian M, Gianni D, Conlon TJ, Fulci G, Brockmann J, Stemmer-Rachamimov A, Sena-Esteves M, Breakefield XO, Brenner GJ. Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1. Human Gene Therapy. 24: 152-62. PMID 23140466 DOI: 10.1089/Hum.2012.094  0.356
2013 Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP, Ströbel T, Breakefield XO, Saydam O. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 101-8. PMID 22910294 DOI: 10.1038/Mt.2012.161  0.348
2013 Abels ER, van der Vos KE, Breakefield XO. Extracellular Vesicle Transfer of MicroRNA by Tumor Cells Aacr Education Book. 2013: 19-24. DOI: 10.1158/AACR.EDB-13-7859  0.302
2012 Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, Hochberg FH, Breakefield XO, Weissleder R, Lee H. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nature Medicine. 18: 1835-40. PMID 23142818 DOI: 10.1038/Nm.2994  0.311
2012 Lai CP, Breakefield XO. Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Frontiers in Physiology. 3: 228. PMID 22754538 DOI: 10.3389/fphys.2012.00228  0.361
2012 Atai NA, Ryan SD, Kothary R, Breakefield XO, Nery FC. Untethering the nuclear envelope and cytoskeleton: biologically distinct dystonias arising from a common cellular dysfunction. International Journal of Cell Biology. 2012: 634214. PMID 22611399 DOI: 10.1155/2012/634214  0.333
2012 Maguire CA, Balaj L, Sivaraman S, Crommentuijn MH, Ericsson M, Mincheva-Nilsson L, Baranov V, Gianni D, Tannous BA, Sena-Esteves M, Breakefield XO, Skog J. Microvesicle-associated AAV vector as a novel gene delivery system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 960-71. PMID 22314290 DOI: 10.1038/Mt.2011.303  0.654
2011 Carter B, Hochberg F, Breakefield X, Balaj L, Sivaraman S, Curry W, Kalkanis SN, Loguidice L, Russo LM, Noerhelm M, Skog J. Use of exosome analysis to reveal glioma-specific genetic changes in patient serum. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2061. PMID 28019922 DOI: 10.1200/Jco.2011.29.15_Suppl.2061  0.35
2011 Wakabayashi-Ito N, Doherty OM, Moriyama H, Breakefield XO, Gusella JF, O'Donnell JM, Ito N. Dtorsin, the Drosophila ortholog of the early-onset dystonia TOR1A (DYT1), plays a novel role in dopamine metabolism. Plos One. 6: e26183. PMID 22022556 DOI: 10.1371/journal.pone.0026183  0.347
2011 Pike LS, Tannous BA, Deliolanis NC, Hsich G, Morse D, Tung CH, Sena-Esteves M, Breakefield XO. Imaging gene delivery in a mouse model of congenital neuronal ceroid lipofuscinosis. Gene Therapy. 18: 1173-8. PMID 21900963 DOI: 10.1038/gt.2011.118  0.38
2011 Breakefield XO, Frederickson RM, Simpson RJ. Gesicles: Microvesicle "cookies" for transient information transfer between cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1574-6. PMID 21886114 DOI: 10.1038/Mt.2011.169  0.334
2011 van der Vos KE, Balaj L, Skog J, Breakefield XO. Brain tumor microvesicles: insights into intercellular communication in the nervous system. Cellular and Molecular Neurobiology. 31: 949-59. PMID 21553248 DOI: 10.1007/s10571-011-9697-y  0.351
2011 Bowers WJ, Breakefield XO, Sena-Esteves M. Genetic therapy for the nervous system. Human Molecular Genetics. 20: R28-41. PMID 21429918 DOI: 10.1093/Hmg/Ddr110  0.335
2011 Bragg DC, Armata IA, Nery FC, Breakefield XO, Sharma N. Molecular pathways in dystonia. Neurobiology of Disease. 42: 136-47. PMID 21134457 DOI: 10.1016/J.Nbd.2010.11.015  0.602
2011 Saydam O, Ozdener GB, Senol O, Mizrak A, Prabhakar S, Stemmer-Rachamimov AO, Breakefield XO, Brenner GJ. A novel imaging-compatible sciatic nerve schwannoma model. Journal of Neuroscience Methods. 195: 75-7. PMID 21111000 DOI: 10.1016/J.Jneumeth.2010.10.021  0.314
2011 Noerholm M, Bentink S, Strand M, Ter-Ovanesyan D, Lundin E, Ohlson N, Ottander U, Balaj L, Limperg T, Salehi A, Zhu LD, Hochberg F, Breakefield X, Carter B, Skog J. Abstract C140: RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and ovarian cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C140  0.348
2010 Breakefield XO, Sena-Esteves M. Healing genes in the nervous system. Neuron. 68: 178-81. PMID 20955923 DOI: 10.1016/j.neuron.2010.10.005  0.331
2010 Chen P, Burdette AJ, Porter JC, Ricketts JC, Fox SA, Nery FC, Hewett JW, Berkowitz LA, Breakefield XO, Caldwell KA, Caldwell GA. The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. Human Molecular Genetics. 19: 3502-15. PMID 20584926 DOI: 10.1093/Hmg/Ddq266  0.312
2010 Grandi P, Fernandez J, Szentirmai O, Carter R, Gianni D, Sena-Esteves M, Breakefield XO. Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Cancer Gene Therapy. 17: 655-63. PMID 20508670 DOI: 10.1038/Cgt.2010.22  0.362
2010 Cao S, Hewett JW, Yokoi F, Lu J, Buckley AC, Burdette AJ, Chen P, Nery FC, Li Y, Breakefield XO, Caldwell GA, Caldwell KA. Chemical enhancement of torsinA function in cell and animal models of torsion dystonia. Disease Models & Mechanisms. 3: 386-96. PMID 20223934 DOI: 10.1242/Dmm.003715  0.352
2010 Prabhakar S, Brenner GJ, Sung B, Messerli SM, Mao J, Sena-Esteves M, Stemmer-Rachamimov A, Tannous B, Breakefield XO. Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter. Cancer Gene Therapy. 17: 266-74. PMID 19834516 DOI: 10.1038/Cgt.2009.71  0.313
2009 Tannous BA, Chiocca EA, Jacobs AH, Corey DP, Breakefield XO. Tannous et al. Respond. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1311-1312. PMID 28160907 DOI: 10.1038/Mt.2009.166  0.307
2009 Tannous BA, Christensen AP, Pike L, Wurdinger T, Perry KF, Saydam O, Jacobs AH, García-Añoveros J, Weissleder R, Sena-Esteves M, Corey DP, Breakefield XO. Mutant sodium channel for tumor therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 810-9. PMID 19259066 DOI: 10.1038/Mt.2009.33  0.357
2008 Schubert M, Breakefield X, Federoff H, Frederickson RM, Lowenstein PR. Gene Delivery to the Nervous System: NINDS Workshop on Gene Delivery to the Nervous System Washington, DC, 12-13 November 2007. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 640-646. PMID 28178462 DOI: 10.1038/Mt.2008.42  0.347
2008 Maguire CA, Meijer DH, LeRoy SG, Tierney LA, Broekman ML, Costa FF, Breakefield XO, Stemmer-Rachamimov A, Sena-Esteves M. Preventing growth of brain tumors by creating a zone of resistance. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1695-702. PMID 18714312 DOI: 10.1038/Mt.2008.168  0.649
2008 Shah K, Hingtgen S, Kasmieh R, Figueiredo JL, Garcia-Garcia E, Martinez-Serrano A, Breakefield X, Weissleder R. Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model Journal of Neuroscience. 28: 4406-4413. PMID 18434519 DOI: 10.1523/Jneurosci.0296-08.2008  0.375
2008 de Oliveira AP, Glauser DL, Laimbacher AS, Strasser R, Schraner EM, Wild P, Ziegler U, Breakefield XO, Ackermann M, Fraefel C. Live visualization of herpes simplex virus type 1 compartment dynamics. Journal of Virology. 82: 4974-90. PMID 18337577 DOI: 10.1128/JVI.02431-07  0.305
2008 Hewett JW, Nery FC, Niland B, Ge P, Tan P, Hadwiger P, Tannous BA, Sah DW, Breakefield XO. siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells. Human Molecular Genetics. 17: 1436-45. PMID 18258738 DOI: 10.1093/hmg/ddn032  0.374
2008 Wurdinger T, Badr C, Pike L, de Kleine R, Weissleder R, Breakefield XO, Tannous BA. A secreted luciferase for ex vivo monitoring of in vivo processes. Nature Methods. 5: 171-3. PMID 18204457 DOI: 10.1038/Nmeth.1177  0.305
2008 Cortés ML, Oehmig A, Saydam O, Sanford JD, Perry KF, Fraefel C, Breakefield XO. Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 81-8. PMID 17998902 DOI: 10.1038/Sj.Mt.6300338  0.401
2008 Kamm C, Ozelius LJ, Breakefield XO. TorsinA and DYT1 early-onset dystonia Future Neurology. 3: 61-72. DOI: 10.2217/14796708.3.1.61  0.354
2007 Oehmig A, Cortés ML, Perry KF, Sena-Esteves M, Fraefel C, Breakefield XO. Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector. Gene Therapy. 14: 1078-91. PMID 17460718 DOI: 10.1038/sj.gt.3302960  0.33
2007 Hewett JW, Tannous B, Niland BP, Nery FC, Zeng J, Li Y, Breakefield XO. Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proceedings of the National Academy of Sciences of the United States of America. 104: 7271-6. PMID 17428918 DOI: 10.1073/Pnas.0701185104  0.318
2007 Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Therapy. 14: 460-7. PMID 17304235 DOI: 10.1038/Sj.Cgt.7701037  0.351
2006 Bahn E, Siegert S, Pfander T, Kramer ML, Schulz-Schaeffer WJ, Hewett JW, Breakefield XO, Hedreen JC, Rostásy KM. TorsinB expression in the developing human brain. Brain Research. 1116: 112-9. PMID 16938275 DOI: 10.1016/j.brainres.2006.07.102  0.374
2006 Cortés ML, Oehmig A, Perry KF, Sanford JD, Breakefield XO. Expression of human ATM cDNA in Atm-deficient mouse brain mediated by HSV-1 amplicon vector. Neuroscience. 141: 1247-56. PMID 16809004 DOI: 10.1016/j.neuroscience.2006.05.055  0.426
2006 Shah K, Breakefield XO. HSV amplicon vectors for cancer therapy. Current Gene Therapy. 6: 361-70. PMID 16787187 DOI: 10.2174/156652306777592063  0.409
2006 Tannous BA, Grimm J, Perry KF, Chen JW, Weissleder R, Breakefield XO. Metabolic biotinylation of cell surface receptors for in vivo imaging. Nature Methods. 3: 391-6. PMID 16628210 DOI: 10.1038/Nmeth875  0.314
2006 McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi MG, Boucher Y, Breakefield XO, Jain RK. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Research. 66: 2509-13. PMID 16510565 DOI: 10.1158/0008-5472.Can-05-2242  0.337
2006 Messerli SM, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Human Gene Therapy. 17: 20-30. PMID 16409122 DOI: 10.1089/Hum.2006.17.20  0.369
2006 Hewett JW, Zeng J, Niland BP, Bragg DC, Breakefield XO. Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. Neurobiology of Disease. 22: 98-111. PMID 16361107 DOI: 10.1016/J.Nbd.2005.10.012  0.639
2006 Kock N, Allchorne AJ, Sena-Esteves M, Woolf CJ, Breakefield XO. RNAi blocks DYT1 mutant torsinA inclusions in neurons. Neuroscience Letters. 395: 201-5. PMID 16332410 DOI: 10.1016/j.neulet.2005.10.098  0.335
2006 Messerli S, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Erratum: Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2 (Human Gene Therapy (January 2006) 17, 1 (20-30)) Human Gene Therapy. 17. DOI: 10.1089/Hum.2006.17.796  0.333
2006 Grandi P, Fernandez J, Szentirmai O, Carter R, Breakefield XO, Sena-Esteves M. 438. Targeting HSV-1 Virions for Specific Binding to Epidermal Growth Factor Receptor-VIII on Tumor Cells Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.504  0.379
2006 Sanford JD, Oehmig A, Perry KF, Breakefield XO, Cortes ML. 252. Targeted Transgene Integration of the Human ATM cDNA Mediated by HSV/AAV Hybrid Amplicon Vector Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.279  0.367
2006 Comer LA, Fernandez JL, Camp SM, Tebbets JC, Breakefield XO, Sena-Esteves M. 154. Tetracycline-Inducible HSV Amplicon Vectors with Expanded Range of Gene Expression Regulation Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.177  0.396
2006 Prabhakar S, Messerli S, Rabkin S, Martuza R, Breakefield XO. 151. Treatment of Experimental Schwannomas with HSV Recombinant and Amplicon Vectors Molecular Therapy. 13: S59. DOI: 10.1016/J.Ymthe.2006.08.174  0.383
2006 Tannous BA, Perry KF, Sena-Esteves M, Garcias-Anoveros J, Jacobs A, Corey DP, Weissleder R, Breakefield XO. 959. Tumor Therapy Via Vector-Regulated Expression of Mutant Sodium Channel Molecular Therapy. 13: S370. DOI: 10.1016/J.Ymthe.2006.08.1051  0.365
2006 Badr CE, Zalloua P, Breakefield XO, Tannous BA. 956. Imaging of Radiation-Inducible Promoters Using a Naturally Secreted Luciferase from the Marine Copepod Gaussia princeps Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.1048  0.336
2005 Brown AB, Mahmood U, Cortes ML, Tang Y, Dai G, Stemmer-Rachamimov A, Prabhakar S, Leishear K, Onda H, Kwiatkowski D, Weissleder R, Breakefield X. Magnetic resonance imaging and characterization of spontaneous lesions in a transgenic mouse model of tuberous sclerosis as a model for endothelial cell-based transgene delivery Human Gene Therapy. 16: 1367-1376. PMID 16390268 DOI: 10.1089/Hum.2005.16.1367  0.331
2005 Siegert S, Bahn E, Kramer ML, Schulz-Schaeffer WJ, Hewett JW, Breakefield XO, Hedreen JC, Rostasy KM. TorsinA expression is detectable in human infants as young as 4 weeks old. Brain Research. Developmental Brain Research. 157: 19-26. PMID 15939081 DOI: 10.1016/j.devbrainres.2005.02.019  0.327
2005 Sharma N, Baxter MG, Petravicz J, Bragg DC, Schienda A, Standaert DG, Breakefield XO. Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 5351-5. PMID 15930383 DOI: 10.1523/Jneurosci.0855-05.2005  0.776
2005 Shah K, Tung CH, Breakefield XO, Weissleder R. In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 926-31. PMID 15922963 DOI: 10.1016/J.Ymthe.2005.01.017  0.304
2005 Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 435-43. PMID 15727940 DOI: 10.1016/J.Ymthe.2004.10.016  0.385
2005 Shah K, Bureau E, Kim DE, Yang K, Tang Y, Weissleder R, Breakefield XO. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Annals of Neurology. 57: 34-41. PMID 15622535 DOI: 10.1002/Ana.20306  0.335
2005 Wang S, Pike L, Petravicz J, Breakefield XO. 164. Bioluminescence Imaging in the CNS after HSV Amplicon Vector Delivery Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.168  0.772
2005 Grandi P, McKee TD, Mok W, Fernandez JL, Breakefield XO, Jain RK. 76. New Strategy To Improve Imaging and Retargeting of HSV-1 Vectors Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.054  0.306
2005 Sharma N, Cristopher Bragg D, Petravicz J, Standaert DG, Breakefield XO. DYT1 transgenic mouse Movement Disorders. 287-292. DOI: 10.1016/B978-012088382-0/50024-4  0.735
2004 Shah K, Hsich G, Breakefield XO. Neural precursor cells and their role in neuro-oncology. Developmental Neuroscience. 26: 118-30. PMID 15711055 DOI: 10.1159/000082132  0.38
2004 Oehmig A, Fraefel C, Breakefield XO, Ackermann M. Herpes simplex virus type 1 amplicons and their hybrid virus partners, EBV, AAV, and retrovirus. Current Gene Therapy. 4: 385-408. PMID 15578989 DOI: 10.2174/1566523043346129  0.382
2004 Bragg DC, Kaufman CA, Kock N, Breakefield XO. Inhibition of N-linked glycosylation prevents inclusion formation by the dystonia-related mutant form of torsinA. Molecular and Cellular Neurosciences. 27: 417-26. PMID 15555920 DOI: 10.1016/J.Mcn.2004.07.009  0.616
2004 Kamm C, Leung J, Joseph S, Dobyns WB, Brashear A, Breakefield XO, Ozelius LJ. Refined linkage to the RDP/DYT12 locus on 19q13.2 and evaluation of GRIK5 as a candidate gene. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 845-7. PMID 15254951 DOI: 10.1002/Mds.20095  0.318
2004 Hewett JW, Kamm C, Boston H, Beauchamp R, Naismith T, Ozelius L, Hanson PI, Breakefield XO, Ramesh V. TorsinB--perinuclear location and association with torsinA. Journal of Neurochemistry. 89: 1186-94. PMID 15147511 DOI: 10.1111/J.1471-4159.2004.02404.X  0.376
2004 Shah K, Tung CH, Yang K, Weissleder R, Breakefield XO. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Research. 64: 3236-42. PMID 15126365 DOI: 10.1158/0008-5472.Can-03-3516  0.35
2004 Grandi P, Spear M, Breakefield XO, Wang S. Targeting HSV amplicon vectors. Methods (San Diego, Calif.). 33: 179-86. PMID 15121173 DOI: 10.1016/J.Ymeth.2003.11.007  0.375
2004 Bragg DC, Camp SM, Kaufman CA, Wilbur JD, Boston H, Schuback DE, Hanson PI, Sena-Esteves M, Breakefield XO. Perinuclear biogenesis of mutant torsin-A inclusions in cultured cells infected with tetracycline-regulated herpes simplex virus type 1 amplicon vectors. Neuroscience. 125: 651-61. PMID 15099679 DOI: 10.1016/J.Neuroscience.2004.01.053  0.627
2004 Lafreniere RG, MacDonald ML, Dube MP, MacFarlane J, O'Driscoll M, Brais B, Meilleur S, Brinkman RR, Dadivas O, Pape T, Platon C, Radomski C, Risler J, Thompson J, Guerra-Escobio AM, ... ... Breakefield XO, et al. Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. American Journal of Human Genetics. 74: 1064-73. PMID 15060842 DOI: 10.1086/420795  0.357
2004 Grandi P, Wang S, Schuback D, Krasnykh V, Spear M, Curiel DT, Manservigi R, Breakefield XO. HSV-1 virions engineered for specific binding to cell surface receptors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 9: 419-27. PMID 15006609 DOI: 10.1016/J.Ymthe.2003.12.010  0.35
2004 Kamm C, Boston H, Hewett J, Wilbur J, Corey DP, Hanson PI, Ramesh V, Breakefield XO. The early onset dystonia protein torsinA interacts with kinesin light chain 1. The Journal of Biological Chemistry. 279: 19882-92. PMID 14970196 DOI: 10.1074/Jbc.M401332200  0.331
2004 Kabakci K, Hedrich K, Leung JC, Mitterer M, Vieregge P, Lencer R, Hagenah J, Garrels J, Witt K, Klostermann F, Svetel M, Friedman J, Kostic V, Bressman SB, Breakefield XO, et al. Mutations in DYT1: extension of the phenotypic and mutational spectrum. Neurology. 62: 395-400. PMID 14872019 DOI: 10.1212/01.WNL.0000113024.84178.F7  0.323
2004 Shah K, Tung CH, Chang CH, Slootweg E, O'Loughlin T, Breakefield XO, Weissleder R. In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. Cancer Research. 64: 273-8. PMID 14729634 DOI: 10.1158/0008-5472.Can-03-1123  0.302
2004 Bragg DC, Slater DJ, Breakefield XO. TorsinA and early-onset torsion dystonia. Advances in Neurology. 94: 87-93. PMID 14509659  0.506
2004 Tang Y, Shah K, Messerli SM, Snyder E, Breakefield X, Weissleder R. In vivo tracking of neural progenitor cell migration to glioblastomas. Human Gene Therapy. 14: 1247-54. PMID 12952596 DOI: 10.1089/104303403767740786  0.353
2004 Wang S, Petravicz J, Breakefield XO. 64. Bioluminescence Imaging of Regulated Gene Expression Using HSV-1 Amplicon Vectors in Rodent Brain Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.05.082  0.779
2004 Cole C, Diaz RM, Forshaw M, Kottke T, Thompson J, Gough M, Breakefield X, Sena-Esteves M, Qiao J, Vile RG. 23. T Cell Carriers for Gene Delivery to Tumors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.05.046  0.37
2003 Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG, Black PM, Breakefield XO, Aboody KS. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Human Gene Therapy. 14: 1777-85. PMID 14670128 DOI: 10.1089/104303403322611782  0.32
2003 Yoshimura S, Teramoto T, Whalen MJ, Irizarry MC, Takagi Y, Qiu J, Harada J, Waeber C, Breakefield XO, Moskowitz MA. FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice. The Journal of Clinical Investigation. 112: 1202-10. PMID 14561705 DOI: 10.1172/JCI16618  0.301
2003 Shah K, Tang Y, Breakefield X, Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene. 22: 6865-72. PMID 14534533 DOI: 10.1038/Sj.Onc.1206748  0.353
2003 Augood SJ, Keller-McGandy CE, Siriani A, Hewett J, Ramesh V, Sapp E, DiFiglia M, Breakefield XO, Standaert DG. Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain. Brain Research. 986: 12-21. PMID 12965225 DOI: 10.1016/S0006-8993(03)03164-0  0.321
2003 Bakowska JC, Di Maria MV, Camp SM, Wang Y, Allen PD, Breakefield XO. Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep(+) hybrid amplicon vector. Gene Therapy. 10: 1691-702. PMID 12923568 DOI: 10.1038/sj.gt.3302061  0.354
2003 Cortés ML, Bakkenist CJ, Di Maria MV, Kastan MB, Breakefield XO. HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Gene Therapy. 10: 1321-7. PMID 12883528 DOI: 10.1038/Sj.Gt.3301996  0.377
2003 Hampl JA, Camp SM, Mydlarz WK, Hampl M, Ichikawa T, Chiocca EA, Louis DN, Sena-Esteves M, Breakefield XO. Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors. Human Gene Therapy. 14: 611-26. PMID 12804144 DOI: 10.1089/104303403321618137  0.391
2003 Wang S, Petravicz J, Breakefield XO. Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 7: 790-800. PMID 12788653 DOI: 10.1016/S1525-0016(03)00094-7  0.787
2003 Davidson BL, Breakefield XO. Viral vectors for gene delivery to the nervous system. Nature Reviews. Neuroscience. 4: 353-64. PMID 12728263 DOI: 10.1038/Nrn1104  0.417
2003 Hewett J, Ziefer P, Bergeron D, Naismith T, Boston H, Slater D, Wilbur J, Schuback D, Kamm C, Smith N, Camp S, Ozelius LJ, Ramesh V, Hanson PI, Breakefield XO. TorsinA in PC12 cells: localization in the endoplasmic reticulum and response to stress. Journal of Neuroscience Research. 72: 158-68. PMID 12671990 DOI: 10.1002/Jnr.10567  0.306
2003 Rostasy K, Augood SJ, Hewett JW, Leung JC, Sasaki H, Ozelius LJ, Ramesh V, Standaert DG, Breakefield XO, Hedreen JC. TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiology of Disease. 12: 11-24. PMID 12609485 DOI: 10.1016/S0969-9961(02)00010-4  0.338
2003 Spear MA, Schuback D, Miyata K, Grandi P, Sun F, Yoo L, Nguyen A, Brandt CR, Breakefield XO. HSV-1 amplicon peptide display vector. Journal of Virological Methods. 107: 71-9. PMID 12445940 DOI: 10.1016/S0166-0934(02)00193-3  0.357
2002 Lam P, Hui KM, Wang Y, Allen PD, Louis DN, Yuan CJ, Breakefield XO. Dynamics of transgene expression in human glioblastoma cells mediated by herpes simplex virus/adeno-associated virus amplicon vectors. Human Gene Therapy. 13: 2147-59. PMID 12542846 DOI: 10.1089/104303402320987842  0.403
2002 Sandler VM, Wang S, Angelo K, Lo HG, Breakefield XO, Clapham DE. Modified herpes simplex virus delivery of enhanced GFP into the central nervous system. Journal of Neuroscience Methods. 121: 211-9. PMID 12468010 DOI: 10.1016/S0165-0270(02)00262-5  0.352
2002 Messerli SM, Tang Y, Giovannini M, Bronson R, Weissleder R, Breakefield XO. Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia (New York, N.Y.). 4: 501-9. PMID 12407444 DOI: 10.1038/Sj.Neo.7900265  0.346
2002 Doheny D, Danisi F, Smith C, Morrison C, Velickovic M, De Leon D, Bressman SB, Leung J, Ozelius L, Klein C, Breakefield XO, Brin MF, Silverman JM. Clinical findings of a myoclonus-dystonia family with two distinct mutations. Neurology. 59: 1244-6. PMID 12391355 DOI: 10.1212/Wnl.59.8.1244  0.319
2002 Sena-Esteves M, Hampl JA, Camp SM, Breakefield XO. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors. The Journal of Gene Medicine. 4: 229-39. PMID 12112640 DOI: 10.1002/jgm.276  0.395
2002 Wang Y, Camp SM, Niwano M, Shen X, Bakowska JC, Breakefield XO, Allen PD. Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration. Journal of Virology. 76: 7150-62. PMID 12072515 DOI: 10.1128/JVI.76.14.7150-7162.2002  0.385
2002 Ziefer P, Leung J, Razzano T, Shalish C, LeDoux MS, Lorden JF, Ozelius L, Breakefield XO, Standaert DG, Augood SJ. Molecular cloning and expression of rat torsinA in the normal and genetically dystonic (dt) rat. Brain Research. Molecular Brain Research. 101: 132-5. PMID 12007841 DOI: 10.1016/S0169-328X(02)00176-6  0.318
2002 Costantini LC, Fraefel C, Breakefield XO, Isacson O. Herpes simplex virus/adeno-associated virus hybrid vectors for gene transfer to neurons. Preparation and use. Methods in Molecular Medicine. 69: 461-79. PMID 11987795 DOI: 10.1385/1-59259-141-8:461  0.322
2002 Hsich G, Sena-Esteves M, Breakefield XO. Critical issues in gene therapy for neurologic disease. Human Gene Therapy. 13: 579-604. PMID 11916483 DOI: 10.1089/10430340252837198  0.376
2002 Wang Y, Mukherjee S, Fraefel C, Breakefield XO, Allen PD. Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle. Human Gene Therapy. 13: 261-73. PMID 11812282 DOI: 10.1089/10430340252769789  0.371
2001 Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, Doheny D, Kamm C, DeLeon D, Pramstaller PP, Penney JB, Eisengart M, Jankovic J, Gasser T, Bressman SB, Corey DP, ... ... Breakefield XO, et al. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics. 3: 133-43. PMID 11523564 DOI: 10.1007/s100480100111  0.321
2001 Spear MA, Breakefield XO, Beltzer J, Schuback D, Weissleder R, Pardo FS, Ladner R. Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. Cancer Gene Therapy. 8: 506-11. PMID 11498772 DOI: 10.1038/Sj.Cgt.7700334  0.339
2001 Breakefield XO, Kamm C, Hanson PI. TorsinA: movement at many levels. Neuron. 31: 9-12. PMID 11498045 DOI: 10.1016/S0896-6273(01)00350-6  0.305
2001 Hedrich K, Kann M, Lanthaler AJ, Dalski A, Eskelson C, Landt O, Schwinger E, Vieregge P, Lang AE, Breakefield XO, Ozelius LJ, Pramstaller PP, Klein C. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Human Molecular Genetics. 10: 1649-56. PMID 11487568 DOI: 10.1093/Hmg/10.16.1649  0.33
2001 Yoshimura S, Takagi Y, Harada J, Teramoto T, Thomas SS, Waeber C, Bakowska JC, Breakefield XO, Moskowitz MA. FGF-2 regulation of neurogenesis in adult hippocampus after brain injury. Proceedings of the National Academy of Sciences of the United States of America. 98: 5874-9. PMID 11320217 DOI: 10.1073/pnas.101034998  0.321
2001 Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Molecular Therapy : the Journal of the American Society of Gene Therapy. 3: 591-601. PMID 11319922 DOI: 10.1006/Mthe.2001.0294  0.321
2001 Lam PY, Breakefield XO. Potential of gene therapy for brain tumors. Human Molecular Genetics. 10: 777-87. PMID 11257112 DOI: 10.1093/Hmg/10.7.777  0.376
2000 Herrlinger U, Jacobs A, Aghi M, Schuback DE, Breakefield XO. HSV-1 Vectors for Gene Therapy of Experimental CNS Tumors. Methods in Molecular Medicine. 35: 287-312. PMID 21390812 DOI: 10.1385/1-59259-086-1:287  0.397
2000 Lam PY, Breakefield XO. Hybrid vector designs to control the delivery, fate and expression of transgenes. The Journal of Gene Medicine. 2: 395-408. PMID 11199260 DOI: 10.1002/1521-2254(200011/12)2:6<395::AID-JGM146>3.0.CO;2-K  0.39
2000 Friedman JR, Klein C, Leung J, Woodward H, Ozelius LJ, Breakefield XO, Charness ME. The GAG deletion of the DYT1 gene is infrequent in musicians with focal dystonia. Neurology. 55: 1417-8. PMID 11087801 DOI: 10.1212/Wnl.55.9.1417  0.337
2000 Schellingerhout D, Rainov NG, Breakefield XO, Weissleder R. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Therapy. 7: 1648-55. PMID 11083473 DOI: 10.1038/Sj.Gt.3301272  0.329
2000 Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proceedings of the National Academy of Sciences of the United States of America. 97: 12846-51. PMID 11070094 DOI: 10.1073/pnas.97.23.12846  0.346
2000 Fraefel C, Jacoby DR, Breakefield XO. Herpes simplex virus type 1-based amplicon vector systems. Advances in Virus Research. 55: 425-51. PMID 11050950 DOI: 10.1016/S0065-3527(00)55011-8  0.381
2000 Herrlinger U, Woiciechowski C, Sena-Esteves M, Aboody KS, Jacobs AH, Rainov NG, Snyder EY, Breakefield XO. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Molecular Therapy : the Journal of the American Society of Gene Therapy. 1: 347-57. PMID 10933953 DOI: 10.1006/mthe.2000.0046  0.379
2000 Klein C, Kann M, Kis B, Pramstaller PP, Breakefield XO, Ozelius LJ, Vieregge P. [Genetics of dystonia]. Der Nervenarzt. 71: 431-41. PMID 10919137 DOI: 10.1007/s001150050604  0.333
2000 Herrlinger U, Jacobs A, Quinones A, Woiciechowsky C, Sena-Esteves M, Rainov NG, Fraefel C, Breakefield XO. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. Human Gene Therapy. 11: 1429-38. PMID 10910140 DOI: 10.1089/10430340050057503  0.359
2000 Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. The Journal of Gene Medicine. 2: 148-64. PMID 10894261 DOI: 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q  0.371
2000 Klein C, Pramstaller PP, Kis B, Page CC, Kann M, Leung J, Woodward H, Castellan CC, Scherer M, Vieregge P, Breakefield XO, Kramer PL, Ozelius LJ. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Annals of Neurology. 48: 65-71. PMID 10894217 DOI: 10.1002/1531-8249(200007)48:1<65::AID-ANA10>3.0.CO;2-L  0.322
2000 Hewett J, Gonzalez-Agosti C, Slater D, Ziefer P, Li S, Bergeron D, Jacoby DJ, Ozelius LJ, Ramesh V, Breakefield XO. Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Human Molecular Genetics. 9: 1403-13. PMID 10814722 DOI: 10.1093/Hmg/9.9.1403  0.355
2000 Sena-Esteves M, Camp SM, Alroy J, Breakefield XO, Kaye EM. Correction of acid beta-galactosidase deficiency in GM1 gangliosidosis human fibroblasts by retrovirus vector-mediated gene transfer: higher efficiency of release and cross-correction by the murine enzyme. Human Gene Therapy. 11: 715-27. PMID 10757351 DOI: 10.1089/10430340050015617  0.342
2000 Costantini LC, Bakowska JC, Breakefield XO, Isacson O. Gene therapy in the CNS. Gene Therapy. 7: 93-109. PMID 10673714 DOI: 10.1038/sj.gt.3301119  0.385
1999 Klein C, Breakefield XO, Ozelius LJ. Genetics of primary dystonia. Seminars in Neurology. 19: 271-80. PMID 12194383 DOI: 10.1055/s-2008-1040843  0.341
1999 Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia (New York, N.Y.). 1: 402-16. PMID 10933055 DOI: 10.1038/Sj.Neo.7900056  0.4
1999 Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis. Neoplasia (New York, N.Y.). 1: 387-401. PMID 10933054 DOI: 10.1038/Sj.Neo.7900055  0.408
1999 Jacobs A, Dubrovin M, Hewett J, Sena-Esteves M, Tan CW, Slack M, Sadelain M, Breakefield XO, Tjuvajev JG. Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia (New York, N.Y.). 1: 154-61. PMID 10933050 DOI: 10.1038/Sj.Neo.7900007  0.388
1999 Pechan PA, Herrlinger U, Aghi M, Jacobs A, Breakefield XO. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. The Journal of Gene Medicine. 1: 176-85. PMID 10738566 DOI: 10.1002/(SICI)1521-2254(199905/06)1:3<176::AID-JGM35>3.0.CO;2-T  0.39
1999 Ozelius LJ, Page CE, Klein C, Hewett JW, Mineta M, Leung J, Shalish C, Bressman SB, de Leon D, Brin MF, Fahn S, Corey DP, Breakefield XO. The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. Genomics. 62: 377-84. PMID 10644435 DOI: 10.1006/geno.1999.6039  0.346
1999 Aghi M, Kramm CM, Breakefield XO. RESPONSE: Re: Folylpolyglutamyl Synthetase Gene Transfer and Glioma Antifolate Sensitivity in Culture and In Vivo. Journal of the National Cancer Institute. 91: 2048-2049. PMID 10580034 DOI: 10.1093/Jnci/91.23.2048  0.301
1999 Sena-Esteves M, Saeki Y, Camp SM, Chiocca EA, Breakefield XO. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. Journal of Virology. 73: 10426-39. PMID 10559361 DOI: 10.1128/Jvi.73.12.10426-10439.1999  0.385
1999 Rainov NG, Ikeda K, Qureshi N, Grover S, Barnett FH, Herrlinger U, Quinones A, Chiocca EA, Breakefield XO. Intra-arterial virus and nonvirus vector-mediated gene transfer to experimental rat brain tumors. Frontiers of Radiation Therapy and Oncology. 33: 227-40. PMID 10549492 DOI: 10.1159/000061238  0.333
1999 Costantini LC, Jacoby DR, Wang S, Fraefel C, Breakefield XO, Isacson O. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Human Gene Therapy. 10: 2481-94. PMID 10543613 DOI: 10.1089/10430349950016825  0.386
1999 Derby ML, Sena-Esteves M, Breakefield XO, Corey DP. Gene transfer into the mammalian inner ear using HSV-1 and vaccinia virus vectors. Hearing Research. 134: 1-8. PMID 10452370 DOI: 10.1016/S0378-5955(99)00045-3  0.397
1999 Barnett FH, Rainov NG, Ikeda K, Schuback DE, Elliott P, Kramm CM, Chase M, Qureshi NH, Harsh G, Chiocca EA, Breakefield XO. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Therapy. 6: 14-20. PMID 10078959 DOI: 10.1038/Sj.Cgt.7700003  0.379
1999 Schuback DE, Mulligan EL, Sims KB, Tivol EA, Greenberg BD, Chang SF, Yang SL, Mau YC, Shen CY, Ho MS, Yang NH, Butler MG, Fink S, Schwartz CE, Berlin F, ... Breakefield XO, et al. Screen for MAOA mutations in target human groups. American Journal of Medical Genetics. 88: 25-8. PMID 10050962 DOI: 10.1002/(Sici)1096-8628(19990205)88:1<25::Aid-Ajmg4>3.0.Co;2-E  0.305
1998 Rainov NG, Sena-Esteves M, Fraefel C, Dobberstein KU, Chiocca EA, Breakefield XO. A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Advances in Experimental Medicine and Biology. 451: 393-403. PMID 10026902 DOI: 10.1007/978-1-4615-5357-1_61  0.421
1998 Klein C, Pramstaller PP, Castellan CC, Breakefield XO, Kramer PL, Ozelius LJ. Clinical and genetic evaluation of a family with a mixed dystonia phenotype from South Tyrol. Annals of Neurology. 44: 394-8. PMID 9749609 DOI: 10.1002/ana.410440318  0.315
1998 Herrlinger U, Kramm CM, Aboody-Guterman KS, Silver JS, Ikeda K, Johnston KM, Pechan PA, Barth RF, Finkelstein D, Chiocca EA, Louis DN, Breakefield XO. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Therapy. 5: 809-19. PMID 9747461 DOI: 10.1038/Sj.Gt.3300643  0.372
1998 Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Philpot RM, Hilton J, Chiocca EA, Breakefield XO. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Human Gene Therapy. 9: 1261-73. PMID 9650611 DOI: 10.1089/Hum.1998.9.9-1261  0.419
1998 Klein C, Brin MF, de Leon D, Limborska SA, Ivanova-Smolenskaya IA, Bressman SB, Friedman A, Markova ED, Risch NJ, Breakefield XO, Ozelius LJ. De novo mutations (GAG deletion) in the DYT1 gene in two non-Jewish patients with early-onset dystonia. Human Molecular Genetics. 7: 1133-6. PMID 9618171 DOI: 10.1093/hmg/7.7.1133  0.312
1998 Bagley J, Aboody-Guterman K, Breakefield X, Iacomini J. Long-term expression of the gene encoding green fluorescent protein in murine hematopoietic cells using retroviral gene transfer. Transplantation. 65: 1233-1240. PMID 9603173 DOI: 10.1097/00007890-199805150-00015  0.36
1998 Augood SJ, Penney JB, Friberg IK, Breakefield XO, Young AB, Ozelius LJ, Standaert DG. Expression of the early-onset torsion dystonia gene (DYT1) in human brain. Annals of Neurology. 43: 669-73. PMID 9585364 DOI: 10.1002/ana.410430518  0.385
1998 Spear MA, Herrlinger U, Rainov N, Pechan P, Weissleder R, Breakefield XO. Targeting gene therapy vectors to CNS malignancies. Journal of Neurovirology. 4: 133-47. PMID 9584951 DOI: 10.3109/13550289809114514  0.371
1998 Murphy DL, Sims K, Eisenhofer G, Greenberg BD, George T, Berlin F, Zametkin A, Ernst M, Breakefield XO. Are MAO-A deficiency states in the general population and in putative high-risk populations highly uncommon? Journal of Neural Transmission. Supplementum. 52: 29-38. PMID 9564605 DOI: 10.1007/978-3-7091-6499-0_4  0.3
1998 Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. Journal of the National Cancer Institute. 90: 370-80. PMID 9498487 DOI: 10.1093/Jnci/90.5.370  0.333
1998 Schellingerhout D, Bogdanov AJ, Marecos E, Spear M, Breakefield X, Weissleder R. Corrigendum: Mapping the in vivo distribution of Herpes simplex virions (Human Gene Therapy (1998) 9, 11) Human Gene Therapy. 9. DOI: 10.1089/10430349850019490  0.301
1997 Fraefel C, Jacoby DR, Lage C, Hilderbrand H, Chou JY, Alt FW, Breakefield XO, Majzoub JA. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Molecular Medicine (Cambridge, Mass.). 3: 813-25. PMID 9440115 DOI: 10.1007/Bf03401718  0.377
1997 Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett FH, Chiocca EA, Breakefield XO. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Human Gene Therapy. 8: 2057-68. PMID 9414254 DOI: 10.1089/hum.1997.8.17-2057  0.369
1997 Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, de Leon D, Brin MF, Raymond D, Corey DP, Fahn S, Risch NJ, Buckler AJ, Gusella JF, Breakefield XO. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nature Genetics. 17: 40-8. PMID 9288096 DOI: 10.1038/ng0997-40  0.333
1997 Paulus W, Baur I, Oberer DM, Breakefield XO, Reeves SA. Regulated expression of the diphtheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements. Journal of Neurosurgery. 87: 89-95. PMID 9202271 DOI: 10.3171/jns.1997.87.1.0089  0.391
1997 Ozelius LJ, Hewett J, Kramer P, Bressman SB, Shalish C, de Leon D, Rutter M, Risch N, Brin MF, Markova ED, Limborska SA, Ivanova-Smolenskaya IA, McCormick MK, Fahn S, Buckler AJ, ... ... Breakefield XO, et al. Fine localization of the torsion dystonia gene (DYT1) on human chromosome 9q34: YAC map and linkage disequilibrium. Genome Research. 7: 483-94. PMID 9149944 DOI: 10.1101/Gr.7.5.483  0.321
1997 Johnston KM, Jacoby D, Pechan PA, Fraefel C, Borghesani P, Schuback D, Dunn RJ, Smith FI, Breakefield XO. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Human Gene Therapy. 8: 359-70. PMID 9048203 DOI: 10.1089/Hum.1997.8.3-359  0.391
1997 Zimmer C, Wright SC, Engelhardt RT, Johnson GA, Kramm C, Breakefield XO, Weissleder R. Tumor cell endocytosis imaging facilitates delineation of the glioma-brain interface. Experimental Neurology. 143: 61-9. PMID 9000446 DOI: 10.1006/Exnr.1996.6350  0.325
1996 Pechan PA, Fotaki M, Thompson RL, Dunn R, Chase M, Chiocca EA, Breakefield XO. A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Human Gene Therapy. 7: 2003-13. PMID 8930661 DOI: 10.1089/Hum.1996.7.16-2003  0.389
1996 Kramm CM, Rainov NG, Sena-Esteves M, Barnett FH, Chase M, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Human Gene Therapy. 7: 1989-94. PMID 8930659 DOI: 10.1089/Hum.1996.7.16-1989  0.371
1996 Battinelli EM, Boyd Y, Craig IW, Breakefield XO, Chen ZY. Characterization and mapping of the mouse NDP (Norrie disease) locus (Ndp). Mammalian Genome : Official Journal of the International Mammalian Genome Society. 7: 93-7. PMID 8835523 DOI: 10.1007/S003359900026  0.369
1996 Kramm CM, Rainov NG, Sena-Esteves M, Chase M, Pechan PA, Chiocca EA, Breakefield XO. Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Human Gene Therapy. 7: 291-300. PMID 8835217 DOI: 10.1089/Hum.1996.7.3-291  0.401
1996 Gasser T, Bove CM, Ozelius LJ, Hallett M, Charness ME, Hochberg FH, Breakefield XO. Haplotype analysis at the DYT1 locus in Ashkenazi Jewish patients with occupational hand dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 11: 163-6. PMID 8684386 DOI: 10.1002/mds.870110208  0.312
1996 Tivol EA, Shalish C, Schuback DE, Hsu YP, Breakefield XO. Mutational analysis of the human MAOA gene. American Journal of Medical Genetics. 67: 92-7. PMID 8678123 DOI: 10.1002/(SICI)1096-8628(19960216)67:1<92::AID-AJMG16>3.0.CO;2-K  0.334
1996 Paulus W, Baur I, Boyce FM, Breakefield XO, Reeves SA. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. Journal of Virology. 70: 62-7. PMID 8523582 DOI: 10.1128/Jvi.70.1.62-67.1996  0.407
1995 Smith F, Jacoby D, Breakefield XO. Virus vectors for gene delivery to the nervous system. Restorative Neurology and Neuroscience. 8: 21-34. PMID 21551801 DOI: 10.3233/RNN-1995-81207  0.392
1995 Kramm CM, Sena-Esteves M, Barnett FH, Rainov NG, Schuback DE, Yu JS, Pechan PA, Paulus W, Chiocca EA, Breakefield XO. Gene therapy for brain tumors. Brain Pathology (Zurich, Switzerland). 5: 345-81. PMID 8974620 DOI: 10.1111/J.1750-3639.1995.Tb00615.X  0.367
1995 Rainov NG, Zimmer C, Chase M, Kramm CM, Chiocca EA, Weissleder R, Breakefield XO. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Human Gene Therapy. 6: 1543-52. PMID 8664379 DOI: 10.1089/Hum.1995.6.12-1543  0.352
1995 Tamiya T, Wei MX, Chase M, Ono Y, Lee F, Breakefield XO, Chiocca EA. Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. Gene Therapy. 2: 531-8. PMID 8593603  0.308
1995 Yoshimoto Y, Lin Q, Collier TJ, Frim DM, Breakefield XO, Bohn MC. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Research. 691: 25-36. PMID 8590062 DOI: 10.1016/0006-8993(95)00596-I  0.308
1995 Chen ZY, Denney RM, Breakefield XO. Norrie disease and MAO genes: nearest neighbors. Human Molecular Genetics. 4: 1729-37. PMID 8541872 DOI: 10.1093/Hmg/4.Suppl_1.1729  0.348
1995 Slaugenhaupt SA, Blumenfeld A, Liebert CB, Mull J, Lucente DE, Monahan M, Breakefield XO, Maayan C, Parada L, Axelrod FB. The human gene for neurotrophic tyrosine kinase receptor type 2 (NTRK2) is located on chromosome 9 but is not the familial dysautonomia gene. Genomics. 25: 730-2. PMID 7759111 DOI: 10.1016/0888-7543(95)80019-I  0.336
1995 Schuback DE, Chen ZY, Craig IW, Breakefield XO, Sims KB. Mutations in the Norrie disease gene. Human Mutation. 5: 285-92. PMID 7627181 DOI: 10.1002/humu.1380050403  0.307
1995 Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, Neuwelt EA. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proceedings of the National Academy of Sciences of the United States of America. 92: 9829-33. PMID 7568227 DOI: 10.1073/Pnas.92.21.9829  0.356
1995 Blumenfeld A, Lucente DE, Trofatter JA, Lerner T, Slaugenhaupt SA, Liebert CB, Monahan M, Haines JL, Gusella JF, Breakefield XO, Parysek LM. Peripherin gene is linked to keratin 18 gene on human chromosome 12. Somatic Cell and Molecular Genetics. 21: 83-8. PMID 7541564 DOI: 10.1007/BF02255825  0.334
1994 Boviatsis EJ, Chase M, Wei MX, Tamiya T, Hurford RK, Kowall NW, Tepper RI, Breakefield XO, Chiocca EA. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Human Gene Therapy. 5: 183-91. PMID 8186298 DOI: 10.1089/Hum.1994.5.2-183  0.401
1994 Davar G, Kramer MF, Garber D, Roca AL, Andersen JK, Bebrin W, Coen DM, Kosz-Vnenchak M, Knipe DM, Breakefield XO. Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors. The Journal of Comparative Neurology. 339: 3-11. PMID 8106660 DOI: 10.1002/Cne.903390103  0.337
1994 Castillo B, del Cerro M, Breakefield XO, Frim DM, Barnstable CJ, Dean DO, Bohn MC. Retinal ganglion cell survival is promoted by genetically modified astrocytes designed to secrete brain-derived neurotrophic factor (BDNF). Brain Research. 647: 30-6. PMID 8069702 DOI: 10.1016/0006-8993(94)91395-1  0.303
1994 Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TK, Kowall NW, Hochberg FH, Waxman DJ, Breakefield XO, Chiocca EA. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Human Gene Therapy. 5: 969-78. PMID 7948146 DOI: 10.1089/Hum.1994.5.8-969  0.371
1994 Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO, Chiocca EA. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Therapy. 1: 323-31. PMID 7584098  0.625
1993 Breakefield XO. Gene delivery into the brain using virus vectors. Nature Genetics. 3: 187-9. PMID 8485570 DOI: 10.1038/ng0393-187  0.347
1993 Hoffman D, Breakefield XO, Short MP, Aebischer P. Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Experimental Neurology. 122: 100-6. PMID 8339781 DOI: 10.1006/exnr.1993.1111  0.308
1993 Chen ZY, Battinelli EM, Hendriks RW, Powell JF, Middleton-Price H, Sims KB, Breakefield XO, Craig IW. Norrie disease gene: characterization of deletions and possible function. Genomics. 16: 533-5. PMID 8314592 DOI: 10.1006/geno.1993.1224  0.387
1993 Dobyns WB, Ozelius LJ, Kramer PL, Brashear A, Farlow MR, Perry TR, Walsh LE, Kasarskis EJ, Butler IJ, Breakefield XO. Rapid-onset dystonia-parkinsonism. Neurology. 43: 2596-602. PMID 8255463 DOI: 10.1212/Wnl.43.12.2596  0.318
1993 Andersen JK, Frim DM, Isacson O, Breakefield XO. Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. Cellular and Molecular Neurobiology. 13: 503-15. PMID 8111822 DOI: 10.1007/Bf00711459  0.385
1993 Blumenfeld A, Slaugenhaupt SA, Axelrod FB, Lucente DE, Maayan C, Liebert CB, Ozelius LJ, Trofatter JA, Haines JL, Breakefield XO. Localization of the gene for familial dysautonomia on chromosome 9 and definition of DNA markers for genetic diagnosis. Nature Genetics. 4: 160-4. PMID 8102296 DOI: 10.1038/ng0693-160  0.309
1993 Frim DM, Short MP, Breakefield XO, Isacson O. Biological Gene-Product Delivery to the Brain: A Protocol for Retroviral Gene Transfer into Cultured Cells and Intracerebral Transplantation Neuroprotocols. 3: 63-68. DOI: 10.1006/Ncmn.1993.1038  0.375
1992 Rosenberg WS, Breakefield XO, DeAntonio C, Isacson O. Authentic and artifactual detection of the E. coli lacZ gene product in the rat brain by histochemical methods. Brain Research. Molecular Brain Research. 16: 311-5. PMID 1337940 DOI: 10.1016/0169-328X(92)90240-C  0.349
1992 Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL, Breakefield XO, Martuza RL. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. Journal of Neuroscience Research. 33: 493-503. PMID 1335091 DOI: 10.1002/jnr.490330316  0.399
1992 Andersen JK, Garber DA, Meaney CA, Breakefield XO. Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Human Gene Therapy. 3: 487-99. PMID 1329993 DOI: 10.1089/hum.1992.3.5-487  0.366
1992 Huang Q, Vonsattel JP, Schaffer PA, Martuza RL, Breakefield XO, DiFiglia M. Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study. Experimental Neurology. 115: 303-16. PMID 1311266 DOI: 10.1016/0014-4886(92)90196-W  0.352
1992 Chen ZY, Sims KB, Coleman M, Donnai D, Monaco A, Breakefield XO, Davies KE, Craig IW. Characterization of a YAC containing part or all of the Norrie disease locus. Human Molecular Genetics. 1: 161-4. PMID 1303171 DOI: 10.1093/Hmg/1.3.161  0.303
1992 Sims KB, Lebo RV, Benson G, Shalish C, Schuback D, Chen ZY, Bruns G, Craig IW, Golbus MS, Breakefield XO. The Norrie disease gene maps to a 150 kb region on chromosome Xp11.3. Human Molecular Genetics. 1: 83-9. PMID 1301161 DOI: 10.1093/Hmg/1.2.83  0.34
1991 Chen ZY, Hotamisligil GS, Huang JK, Wen L, Ezzeddine D, Aydin-Muderrisoglu N, Powell JF, Huang RH, Breakefield XO, Craig I. Structure of the human gene for monoamine oxidase type A. Nucleic Acids Research. 19: 4537-41. PMID 1886775 DOI: 10.1093/Nar/19.16.4537  0.338
1991 Schuback D, Kramer P, Ozelius L, Holmgren G, Forsgren L, Kyllerman M, Wahlström J, Craft CM, Nygaard T, Brin M, de Leon D, Bressman S, Moskowitz CB, Burke RE, Sanner G, ... ... Breakefield XO, et al. Dopamine beta-hydroxylase gene excluded in four subtypes of hereditary dystonia Human Genetics. 87: 311-316. PMID 1677923 DOI: 10.1007/BF00200910  0.335
1991 Cunningham LA, Short MP, Vielkind U, Breakefield XO, Bohn MC. Survival and differentiation within the adult mouse striatum of grafted rat pheochromocytoma cells (PC12) genetically modified to express recombinant beta-NGF. Experimental Neurology. 112: 174-82. PMID 1674694 DOI: 10.1016/0014-4886(91)90067-M  0.332
1990 Diergaarde PJ, Wieringa B, Bleeker-Wagemakers EM, Sims KB, Breakefield XO, Ropers HH. Physical fine-mapping of a deletion spanning the Norrie gene. Human Genetics. 84: 22-6. PMID 2606473 DOI: 10.1007/BF00210665  0.318
1990 Ozelius L, Gusella JF, Breakefield XO. MspI RFLP for human MAOA gene. Nucleic Acids Research. 17: 10516. PMID 2481273 DOI: 10.1093/NAR/17.24.10516  0.313
1990 Short MP, Choi BC, Lee JK, Malick A, Breakefield XO, Martuza RL. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. Journal of Neuroscience Research. 27: 427-39. PMID 2129047 DOI: 10.1002/Jnr.490270322  0.378
1990 Short MP, Rosenberg MB, Ezzedine ZD, Gage FH, Friedmann T, Breakefield XO. Autocrine differentiation of PC12 cells mediated by retroviral vectors. Developmental Neuroscience. 12: 34-45. PMID 2105198 DOI: 10.1159/000111833  0.344
1990 Seizinger BR, Breakefield XO. The role of 'tumor suppressor' genes in neural tumors. Trends in Neurosciences. 13: 3-6. PMID 1688673 DOI: 10.1016/0166-2236(90)90050-K  0.375
1989 Breakefield XO, Geller AI. Gene transfer into the nervous system. Molecular Neurobiology. 1: 339-71. PMID 3077063 DOI: 10.1007/BF02935741  0.378
1989 Breakefield XO. Combining CNS transplantation and gene transfer. Neurobiology of Aging. 10: 647-8; discussion 64. PMID 2812248 DOI: 10.1016/0197-4580(89)90167-X  0.333
1989 Shimohama S, Rosenberg MB, Fagan AM, Wolff JA, Short MP, Breakefield XO, Friedmann T, Gage FH. Grafting genetically modified cells into the rat brain: characteristics of E. coli beta-galactosidase as a reporter gene. Brain Research. Molecular Brain Research. 5: 271-8. PMID 2501628 DOI: 10.1016/0169-328X(89)90061-2  0.32
1988 Rosenberg MB, Friedmann T, Robertson RC, Tuszynski M, Wolff JA, Breakefield XO, Gage FH. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science (New York, N.Y.). 242: 1575-8. PMID 3201248 DOI: 10.1126/Science.3201248  0.316
1988 Ozelius L, Hsu YPP, Bruns G, Powell JF, Chen S, Weyler W, Utterback M, Zucker D, Haines J, Trofatter JA, Conneally PM, Gusella JF, Breakefield XO. Human monoamine oxidase gene (MAOA): Chromosome position (Xp21-p11) and DNA polymorphism Genomics. 3: 53-58. PMID 2906043 DOI: 10.1016/0888-7543(88)90159-0  0.319
1988 Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons Science. 241: 1667-1669. PMID 2843986 DOI: 10.1126/Science.2843986  0.366
1987 Seizinger BR, Martuza RL, Rouleau G, Breakefield XO, Gusella JF. Models for inherited susceptibility to cancer in the nervous system: a molecular-genetic approach to neurofibromatosis. Developmental Neuroscience. 9: 144-53. PMID 3119309 DOI: 10.1159/000111618  0.363
1987 Rosenberg MB, Breakefield XO, Hawrot E. Targeting of Liposomes to Cells Bearing Nerve Growth Factor Receptors Mediated by Biotinylated Nerve Growth Factor Journal of Neurochemistry. 48: 865-875. PMID 3027260 DOI: 10.1111/J.1471-4159.1987.Tb05597.X  0.306
1987 Seizinger BR, Rouleau GA, Lane AH, Farmer G, Ozelius LJ, Haines JL, Parry DM, Korf BR, Pericak-Vance MA, Faryniarz AG, Hobbs WJ, Iannazzi JA, Roy JC, Menon A, Bader JL, ... ... Breakefield XO, et al. Linkage analysis in von Recklinghausen neurofibromatosis (NF1) with DNA markers for chromosome 17 Genomics. 1: 346-348. PMID 2896628 DOI: 10.1016/0888-7543(87)90035-8  0.305
1986 Brockes JP, Breakefield XO, Martuza RL. Glial growth factor-like activity in Schwann cell tumors. Annals of Neurology. 20: 317-22. PMID 3767316 DOI: 10.1002/Ana.410200308  0.324
1986 Breakefield XO, Bressman SB, Kramer PL, Ozelius L, Moskowitz C, Tanzi R, Brin MF, Hobbs W, Kaufman D, Tobin A. Linkage analysis in a family with dominantly inherited torsion dystonia: exclusion of the pro-opiomelanocortin and glutamic acid decarboxylase genes and other chromosomal regions using DNA polymorphisms. Journal of Neurogenetics. 3: 159-75. PMID 3016220 DOI: 10.3109/01677068609106846  0.324
1986 Breakefield XO, Stern DF. Oncogenes in neural tumors Trends in Neurosciences. 9: 150-155. DOI: 10.1016/0166-2236(86)90051-2  0.352
1983 Breakefield XO, Hansen CR. Do DNA rearrangements occur in neuronal development? Clues from an inherited human disease Trends in Neurosciences. 6: 444-446. DOI: 10.1016/0166-2236(83)90215-1  0.343
1981 Hawkins M, Wallace DC, Eisenstadt JM, Breakefield XO. Expression of monoamine oxidase A and B activities in mouse cybrids and hybrids. Life Sciences. 28: 425-432. PMID 7219055 DOI: 10.1016/0024-3205(81)90089-8  0.347
1981 Pintar J, Barbosa J, Francke U, Castiglione C, Hawkins M, Breakefield X. Gene for monoamine oxidase type A assigned to the human X chromosome. The Journal of Neuroscience. 1: 166-175. DOI: 10.1523/Jneurosci.01-02-00166.1981  0.31
1979 Castrocosta MR, Breakefield XO. Distinct forms of monoamine oxidase expressed in hepatoma and HeLa cells in culture. Biochemical Pharmacology. 28: 525-528. PMID 426872 DOI: 10.1016/0006-2952(79)90246-6  0.307
1979 Walter U, Costa MR, Breakefield XO, Greengard P. Presence of free cyclic AMP receptor protein and regulation of its level by cyclic AMP in neuroblastoma-glioma hybrid cells. Proceedings of the National Academy of Sciences of the United States of America. 76: 3251-5. PMID 226964 DOI: 10.1073/pnas.76.7.3251  0.304
1978 Breakefield XO, Castiglione CM, Halaban R, Pawelek J, Shiman R. Phenylalanine hydroxylase in melanoma cells. Journal of Cellular Physiology. 94: 307-14. PMID 23386 DOI: 10.1002/JCP.1040940308  0.302
1975 Breakefield XO, Neale EA, Neale JH, Jacobowitz DM. Localized catecholamine storage associated with granules in murine neuroblastoma cells Brain Research. 92: 237-256. PMID 240485 DOI: 10.1016/0006-8993(75)90273-5  0.304
1974 Breakefield XO, Nirenberg MW. Selection for neuroblastoma cells that synthesize certain transmitters. Proceedings of the National Academy of Sciences of the United States of America. 71: 2530-3. PMID 4152249 DOI: 10.1073/Pnas.71.6.2530  0.547
Low-probability matches (unlikely to be authored by this person)
1996 Davar G, Shalish C, Blumenfeld A, Breakefield XO. Exclusion of p75(NGFR) and other candidate genes in a family with hereditary sensory neuropathy Type II Pain. 67: 135-139. PMID 8895241 DOI: 10.1016/0304-3959(96)03113-2  0.3
1995 Hsu YP, Schuback DE, Tivol EA, Shalish C, Murphy DL, Breakefield XO. Analysis of MAOA mutations in humans. Progress in Brain Research. 106: 67-75. PMID 8584675 DOI: 10.1016/S0079-6123(08)61203-0  0.299
1990 Murphy DL, Sims KB, Karoum F, Chapelle Adl, Norio R, Sankila E-, Breakefield XO. Marked Amine and Amine Metabolite Changes in Norrie Disease Patients with an X‐Chromosomal Deletion Affecting Monoamine Oxidase Journal of Neurochemistry. 54: 242-247. PMID 2293615 DOI: 10.1111/J.1471-4159.1990.Tb13307.X  0.299
1995 Isacson O, Frim DM, Galpern WR, Tatter SB, Breakefield XO, Schumacher JM. Cell-mediated delivery of neurotrophic factors and neuroprotection in the neostriatum and substantia nigra. Restorative Neurology and Neuroscience. 8: 59-61. PMID 21551807 DOI: 10.3233/Rnn-1995-81213  0.299
1980 Breakefield XO, Edelstein SB. Inherited Levels of A and B Types of Monoamine Oxidase Activity Schizophrenia Bulletin. 6: 282-288. PMID 6929569 DOI: 10.1093/Schbul/6.2.282  0.298
2004 Shah K, Jacobs A, Breakefield XO, Weissleder R. Molecular imaging of gene therapy for cancer. Gene Therapy. 11: 1175-87. PMID 15141158 DOI: 10.1038/Sj.Gt.3302278  0.298
2020 Dusoswa SA, Verhoeff J, Abels E, Méndez-Huergo SP, Croci DO, Kuijper LH, de Miguel E, Wouters VMCJ, Best MG, Rodriguez E, Cornelissen LAM, van Vliet SJ, Wesseling P, Breakefield XO, Noske DP, et al. Glioblastomas exploit truncated Olinked glycans for local and distant immune modulation via the macrophage galactose-type lectin. Proceedings of the National Academy of Sciences of the United States of America. PMID 32019882 DOI: 10.1073/pnas.1907921117  0.297
1993 Frim DM, Short MP, Rosenberg WS, Simpson J, Breakefield XO, Isacson O. Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum. Journal of Neurosurgery. 78: 267-73. PMID 8421209 DOI: 10.3171/Jns.1993.78.2.0267  0.297
2008 Breakefield XO, Blood AJ, Li Y, Hallett M, Hanson PI, Standaert DG. The pathophysiological basis of dystonias. Nature Reviews. Neuroscience. 9: 222-34. PMID 18285800 DOI: 10.1038/Nrn2337  0.297
2015 Chadwick LH, Sawa A, Yang IV, Baccarelli A, Breakefield XO, Deng HW, Dolinoy DC, Fallin MD, Holland NT, Houseman EA, Lomvardas S, Rao M, Satterlee JS, Tyson FL, Vijayanand P, et al. New insights and updated guidelines for epigenome-wide association studies Neuroepigenetics. 1: 14-19. DOI: 10.1016/J.Nepig.2014.10.004  0.296
2011 Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, Skog J. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nature Communications. 2: 180. PMID 21285958 DOI: 10.1038/Ncomms1180  0.296
1991 Ezzeddine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, Breakefield XO. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. The New Biologist. 3: 608-14. PMID 1655012  0.295
1997 Bressman SB, de Leon D, Raymond D, Greene PE, Brin MF, Fahn S, Ozelius LJ, Breakefield XO, Kramer PL, Risch NJ. Secondary dystonia and the DYTI gene. Neurology. 48: 1571-7. PMID 9191768 DOI: 10.1212/WNL.48.6.1571  0.294
2012 Wurdinger T, Gatson NN, Balaj L, Kaur B, Breakefield XO, Pegtel DM. Extracellular vesicles and their convergence with viral pathways. Advances in Virology. 2012: 767694. PMID 22888349 DOI: 10.1155/2012/767694  0.294
1999 Kramer PL, Mineta M, Klein C, Schilling K, de Leon D, Farlow MR, Breakefield XO, Bressman SB, Dobyns WB, Ozelius LJ, Brashear A. Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13. Annals of Neurology. 46: 176-82. PMID 10443882 DOI: 10.1002/1531-8249(199908)46:2<176::Aid-Ana6>3.0.Co;2-2  0.294
1990 Bonnefil V, Castiglione CM, Cawthon RM, Breakefield XO. Effect of riboflavin on monoamine oxidase activity in cultured neuroblastoma cells. Cellular and Molecular Neurobiology. 1: 351-9. PMID 6765737 DOI: 10.1007/BF00716270  0.293
2006 Vasudevan A, Breakefield XO, Bhide PG. Developmental patterns of torsinA and torsinB expression. Brain Research. 1073: 139-45. PMID 16458269 DOI: 10.1016/J.Brainres.2005.12.087  0.293
1992 Chen ZY, Powell JF, Hsu YP, Breakefield XO, Craig IW. Organization of the human monoamine oxidase genes and long-range physical mapping around them. Genomics. 14: 75-82. PMID 1427833 DOI: 10.1016/S0888-7543(05)80286-1  0.292
1989 Levy ER, Powell JF, Buckle VJ, Hsu YPP, Breakefield XO, Craig IW. Localization of human monoamine oxidase-A gene to Xp11.23-11.4 by in situ hybridization: Implications for norrie disease Genomics. 5: 368-370. PMID 2793188 DOI: 10.1016/0888-7543(89)90072-4  0.292
2018 Fraser K, Jo A, Giedt J, Vinegoni C, Yang KS, Peruzzi P, Chiocca EA, Breakefield XO, Lee H, Weissleder R. Characterization of single microvesicles in plasma from glioblastoma patients. Neuro-Oncology. PMID 30561734 DOI: 10.1093/Neuonc/Noy187  0.292
2015 György B, Hung ME, Breakefield XO, Leonard JN. Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annual Review of Pharmacology and Toxicology. 55: 439-64. PMID 25292428 DOI: 10.1146/Annurev-Pharmtox-010814-124630  0.292
1994 Gasser T, Wszolek ZK, Trofatter J, Ozelius L, Uitti RJ, Lee CS, Gusella J, Pfeiffer RF, Calne DB, Breakefield XO. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Annals of Neurology. 36: 387-96. PMID 7915897 DOI: 10.1002/Ana.410360310  0.292
2002 Pramstaller PP, Kis B, Eskelson C, Hedrich K, Scherer M, Schwinger E, Breakefield XO, Kramer PL, Ozelius LJ, Klein C. Phenotypic variability in a large kindred (Family LA) with deletions in the parkin gene. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 424-6. PMID 11921141 DOI: 10.1002/mds.10071  0.292
1998 Saeki Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M, Breakefield XO, Fraefel C. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Human Gene Therapy. 9: 2787-94. PMID 9874276 DOI: 10.1089/Hum.1998.9.18-2787  0.291
1991 Schumacher JM, Short MP, Hyman BT, Breakefield XO, Isacson O. Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. Neuroscience. 45: 561-70. PMID 1837849 DOI: 10.1016/0306-4522(91)90271-O  0.291
1978 Lloyd T, Weisz J, Breakefield XO. The catechol estrogen, 2-hydroxyestradiol, inhibits catechol-o-methyltransferase activity in neuroblastoma cells. Journal of Neurochemistry. 31: 245-250. PMID 671023 DOI: 10.1111/J.1471-4159.1978.Tb12455.X  0.291
2016 Pucci F, Garris C, Lai CP, Newton A, Pfirschke C, Engblom C, Alvarez D, Sprachman M, Evavold C, Magnuson A, von Andrian UH, Glatz K, Breakefield XO, Mempel TR, Weissleder R, et al. SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science (New York, N.Y.). PMID 26989197 DOI: 10.1126/Science.Aaf1328  0.291
1975 Breakefield XO. Reserpine sensitivity of catecholamine metabolism in murine neuroblastoma clone N1E-115. Journal of Neurochemistry. 25: 877-882. PMID 1206405 DOI: 10.1111/J.1471-4159.1975.Tb04421.X  0.291
2000 Sena-Esteves M, Saeki Y, Fraefel C, Breakefield XO. HSV-1 amplicon vectors--simplicity and versatility. Molecular Therapy : the Journal of the American Society of Gene Therapy. 2: 9-15. PMID 10899823 DOI: 10.1006/mthe.2000.0096  0.29
1993 Blumenfeld A, Axelrod FB, Trofatter JA, Maayan C, Lucente DE, Slaugenhaupt SA, Liebert CB, Ozelius LJ, Haines JL, Breakefield XO. Exclusion of familial dysautonomia from more than 60% of the genome. Journal of Medical Genetics. 30: 47-52. PMID 8093738 DOI: 10.1136/Jmg.30.1.47  0.29
1998 Klein C, Ozelius LJ, Hagenah J, Breakefield XO, Risch NJ, Vieregge P. Search for a founder mutation in idiopathic focal dystonia from Northern Germany. American Journal of Human Genetics. 63: 1777-82. PMID 9837831 DOI: 10.1086/302143  0.29
2007 Balcioglu A, Kim MO, Sharma N, Cha JH, Breakefield XO, Standaert DG. Dopamine release is impaired in a mouse model of DYT1 dystonia. Journal of Neurochemistry. 102: 783-8. PMID 17550429 DOI: 10.1111/J.1471-4159.2007.04590.X  0.29
2013 EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nature Reviews. Drug Discovery. 12: 347-57. PMID 23584393 DOI: 10.1038/nrd3978  0.29
1984 Breakefield XO, Orloff G, Castiglione C, Coussens L, Axelrod FB, Ullrich A. Structural gene for beta-nerve growth factor not defective in familial dysautonomia. Proceedings of the National Academy of Sciences of the United States of America. 81: 4213-6. PMID 6330750 DOI: 10.1073/Pnas.81.13.4213  0.29
1994 Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proceedings of the National Academy of Sciences of the United States of America. 91: 5104-8. PMID 8197193 DOI: 10.1073/Pnas.91.11.5104  0.289
2017 Speranza MC, Passaro C, Ricklefs F, Kasai K, Klein SR, Nakashima H, Kaufmann JK, Ahmed AK, Nowicki MO, Obi P, Bronisz A, Aguilar-Cordova E, Aguilar LK, Guzik BW, Breakefield X, et al. Preclinical investigation of gene-mediated cytotoxic immunotherapy and checkpoint blockade in glioblastoma. Neuro-Oncology. PMID 29016938 DOI: 10.1093/Neuonc/Nox139  0.289
2006 Kock N, Naismith TV, Boston HE, Ozelius LJ, Corey DP, Breakefield XO, Hanson PI. Effects of genetic variations in the dystonia protein torsinA: identification of polymorphism at residue 216 as protein modifier. Human Molecular Genetics. 15: 1355-64. PMID 16537570 DOI: 10.1093/Hmg/Ddl055  0.289
2002 Wang S, Fraefel C, Breakefield X. HSV-1 amplicon vectors. Methods in Enzymology. 346: 593-603. PMID 11883093 DOI: 10.1016/S0076-6879(02)46079-X  0.289
2012 Breakefield XO. Refocus the recombinant DNA advisory committee. Nature Medicine. 18: 1007. PMID 22772546 DOI: 10.1038/nm0712-1007  0.289
1976 Breakefield XO. Neurotransmitter metabolism in murine neuroblastoma cells. Life Sciences. 18: 267-278. PMID 3710 DOI: 10.1016/0024-3205(76)90055-2  0.288
1993 Frim DM, Simpson J, Uhler TA, Short MP, Bossi SR, Breakefield XO, Isacson O. Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. Journal of Neuroscience Research. 35: 452-8. PMID 8103116 DOI: 10.1002/Jnr.490350413  0.288
1987 Pintar JE, Breakefield XO, Patterson PH. Differences in monoamine oxidase activity between cultured noradrenergic and cholinergic sympathetic neurons. Developmental Biology. 120: 305-8. PMID 3817298 DOI: 10.1016/0012-1606(87)90128-X  0.287
2018 Antoury L, Hu N, Balaj L, Das S, Georghiou S, Darras B, Clark T, Breakefield XO, Wheeler TM. Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nature Communications. 9: 3906. PMID 30254196 DOI: 10.1038/S41467-018-06206-0  0.287
1978 Hawkins M, Breakefield XO. Monoamine Oxidase A And B In Cultured Cells Journal of Neurochemistry. 30: 1391-1397. PMID 209133 DOI: 10.1111/J.1471-4159.1978.Tb10471.X  0.287
2012 Breakefield XO. The ASGCT in 2012: Charting a Path to Bring Novel Biologic Therapies to the Clinic. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1289-1290. PMID 28178492 DOI: 10.1038/mt.2012.122  0.287
1997 Aboody-Guterman KS, Pechan PA, Rainov NG, Sena-Esteves M, Jacobs A, Snyder EY, Wild P, Schraner E, Tobler K, Breakefield XO, Fraefel C. Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo. Neuroreport. 8: 3801-8. PMID 9427374  0.287
2001 Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, Larson SM, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO, Blasberg RG. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Research. 61: 2983-95. PMID 11306477  0.287
1996 Rainov NG, Kramm CM, Aboody-Guterman K, Chase M, Ueki K, Louis DN, Harsh GR, Chiocca A, Breakefield XO. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Therapy. 3: 99-106. PMID 8729908  0.287
2010 Chen C, Skog J, Hsu CH, Lessard RT, Balaj L, Wurdinger T, Carter BS, Breakefield XO, Toner M, Irimia D. Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab On a Chip. 10: 505-11. PMID 20126692 DOI: 10.1039/B916199F  0.286
2002 Klein C, Liu L, Doheny D, Kock N, Müller B, de Carvalho Aguiar P, Leung J, de Leon D, Bressman SB, Silverman J, Smith C, Danisi F, Morrison C, Walker RH, Velickovic M, ... ... Breakefield XO, et al. Epsilon-sarcoglycan mutations found in combination with other dystonia gene mutations. Annals of Neurology. 52: 675-9. PMID 12402271 DOI: 10.1002/ana.10358  0.286
1999 Klein C, Brin MF, Kramer P, Sena-Esteves M, de Leon D, Doheny D, Bressman S, Fahn S, Breakefield XO, Ozelius LJ. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proceedings of the National Academy of Sciences of the United States of America. 96: 5173-6. PMID 10220438 DOI: 10.1073/pnas.96.9.5173  0.286
1999 Augood SJ, Martin DM, Ozelius LJ, Breakefield XO, Penney JB, Standaert DG. Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain. Annals of Neurology. 46: 761-9. PMID 10553994 DOI: 10.1002/1531-8249(199911)46:5<761::AID-ANA12>3.0.CO;2-Z  0.286
1999 Klein C, Page CE, LeWitt P, Gordon MF, de Leon D, Awaad Y, Breakefield XO, Brin MF, Ozelius LJ. Genetic analysis of three patients with an 18p- syndrome and dystonia. Neurology. 52: 649-51. PMID 10025808 DOI: 10.1212/Wnl.52.3.649  0.286
2008 Nery FC, Zeng J, Niland BP, Hewett J, Farley J, Irimia D, Li Y, Wiche G, Sonnenberg A, Breakefield XO. TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton. Journal of Cell Science. 121: 3476-86. PMID 18827015 DOI: 10.1242/Jcs.029454  0.286
2014 Nery FC, da Hora CC, Atai NA, Kim EY, Hettich J, Mempel TR, Breakefield XO, Irimia D. Microfluidic platform to evaluate migration of cells from patients with DYT1 dystonia. Journal of Neuroscience Methods. 232: 181-8. PMID 24880044 DOI: 10.1016/J.Jneumeth.2014.05.027  0.285
1992 Haines JL, Yan WL, Boustany RM, Jewell A, Julier C, Breakefield XO, Gusella JF. Linkage analysis in juvenile neuronal ceroid lipofuscinosis. American Journal of Medical Genetics. 42: 542-5. PMID 1609835 DOI: 10.1002/Ajmg.1320420424  0.285
2011 Nery FC, Armata IA, Farley JE, Cho JA, Yaqub U, Chen P, da Hora CC, Wang Q, Tagaya M, Klein C, Tannous B, Caldwell KA, Caldwell GA, Lencer WI, Ye Y, ... Breakefield XO, et al. TorsinA participates in endoplasmic reticulum-associated degradation. Nature Communications. 2: 393. PMID 21750546 DOI: 10.1038/Ncomms1383  0.284
2004 Messerli SM, Prabhakar S, Tang Y, Shah K, Cortes ML, Murthy V, Weissleder R, Breakefield XO, Tung CH. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia (New York, N.Y.). 6: 95-105. PMID 15140398 DOI: 10.1593/Neo.03214  0.284
1981 Ryan JM, Ostrow DG, Breakefield XO, Gershon ES, Upchurch L. A comparison of the proliferative and replicative life span kinetics of cell cultures derived from monozygotic twins. In Vitro Cellular & Developmental Biology – Plant. 17: 20-27. PMID 7194310 DOI: 10.1007/Bf02618026  0.283
2017 Wei Z, Batagov AO, Schinelli S, Wang J, Wang Y, El Fatimy R, Rabinovsky R, Balaj L, Chen CC, Hochberg F, Carter B, Breakefield XO, Krichevsky AM. Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. Nature Communications. 8: 1145. PMID 29074968 DOI: 10.1038/S41467-017-01196-X  0.283
1993 Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science (New York, N.Y.). 262: 578-80. PMID 8211186 DOI: 10.1126/Science.8211186  0.283
1982 Pintar JE, Breakefield XO. Monoamine oxidase (MAO) activity as a determinant in human neurophysiology. Behavior Genetics. 12: 53-68. PMID 6284115 DOI: 10.1007/BF01065740  0.283
2004 Oehmig A, Fraefel C, Breakefield XO. Update on herpesvirus amplicon vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 630-43. PMID 15451447 DOI: 10.1016/j.ymthe.2004.06.641  0.282
1999 Rainov NG, Ikeda K, Qureshi NH, Grover S, Herrlinger U, Pechan P, Chiocca EA, Breakefield XO, Barnett FH. Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Human Gene Therapy. 10: 311-8. PMID 10022555 DOI: 10.1089/10430349950019093  0.282
1994 Andersen JK, Frim DM, Isacson O, Beal MF, Breakefield XO. Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain Research. 656: 108-14. PMID 7804823 DOI: 10.1016/0006-8993(94)91371-4  0.282
1983 Pintar JE, Levitt P, Salach JI, Weyler W, Rosenberg MB, Breakefield XO. Specificity of antisera prepared against pure bovine MAO-B. Brain Research. 276: 127-39. PMID 6626992 DOI: 10.1016/0006-8993(83)90554-1  0.282
1973 Breakefield XO, Landman OE. Temperature-Sensitive Divisionless Mutant of Bacillus subtilis Defective in the Initiation of Septation Journal of Bacteriology. 113: 985-998. PMID 4570614 DOI: 10.1128/Jb.113.2.985-998.1973  0.281
2002 Opal P, Tintner R, Jankovic J, Leung J, Breakefield XO, Friedman J, Ozelius L. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 339-45. PMID 11921121 DOI: 10.1002/mds.10096  0.281
2002 Kann M, Jacobs H, Mohrmann K, Schumacher K, Hedrich K, Garrels J, Wiegers K, Schwinger E, Pramstaller PP, Breakefield XO, Ozelius LJ, Vieregge P, Klein C. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Annals of Neurology. 51: 621-5. PMID 12112109 DOI: 10.1002/ana.10179  0.281
1981 Breakefield XO, Braverman M, Riker DK, Giller EL. Cathechol‐O‐methyltransferase activity in cultured human skin fibroblasts from controls and patients with dystonia musculorum deformans Journal of Neuroscience Research. 6: 349-360. PMID 7299845 DOI: 10.1002/Jnr.490060310  0.28
2015 van der Vos KE, Abels ER, Zhang X, Lai C, Carrizosa E, Oakley D, Prabhakar S, Mardini O, Crommentuijn MH, Skog J, Krichevsky AM, Stemmer-Rachamimov A, Mempel TR, El Khoury J, Hickman SE, ... Breakefield XO, et al. Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro-Oncology. PMID 26433199 DOI: 10.1093/Neuonc/Nov244  0.28
2012 Noerholm M, Balaj L, Limperg T, Salehi A, Zhu LD, Hochberg FH, Breakefield XO, Carter BS, Skog J. RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. Bmc Cancer. 12: 22. PMID 22251860 DOI: 10.1186/1471-2407-12-22  0.279
1999 Klein C, Friedman J, Bressman S, Vieregge P, Brin MF, Pramstaller PP, De Leon D, Hagenah J, Sieberer M, Fleet C, Kiely R, Xin W, Breakefield XO, Ozelius LJ, Sims KB. Genetic testing for early-onset torsion dystonia (DYT1): introduction of a simple screening method, experiences from testing of a large patient cohort, and ethical aspects. Genetic Testing. 3: 323-8. PMID 10627938 DOI: 10.1089/Gte.1999.3.323  0.279
2016 Soares VY, Atai NA, Fujita T, Dilwali S, Sivaraman S, Landegger LD, Hochberg FH, Oliveira CA, Bahmad F, Breakefield XO, Stankovic KM. Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells. Neuro-Oncology. PMID 27194145 DOI: 10.1093/neuonc/now099  0.279
1993 Frim DM, Uhler TA, Short MP, Ezzedine ZD, Klagsbrun M, Breakefield XO, Isacson O. Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. Neuroreport. 4: 367-70. PMID 8098961 DOI: 10.1097/00001756-199304000-00006  0.278
2015 Nery FC, da Hora CC, Yaqub U, Zhang X, McCarthy DM, Bhide PG, Irimia D, Breakefield XO. New methods for investigation of neuronal migration in embryonic brain explants. Journal of Neuroscience Methods. 239: 80-4. PMID 25291524 DOI: 10.1016/J.Jneumeth.2014.09.028  0.278
1976 Rotman A, Daly JW, Creveling CR, Breakefield XO. Uptake and binding of dopamine and 6-hydroxydopamine in murine neuroblastoma and fibroblast cells Biochemical Pharmacology. 25: 383-388. PMID 945744 DOI: 10.1016/0006-2952(76)90337-3  0.277
2007 Badr CE, Hewett JW, Breakefield XO, Tannous BA. A highly sensitive assay for monitoring the secretory pathway and ER stress. Plos One. 2: e571. PMID 17593970 DOI: 10.1371/journal.pone.0000571  0.277
1976 Breakefield X, Castiglione C, Edelstein S. Monoamine oxidase activity decreased in cells lacking hypoxanthine phosphoribosyltransferase activity. Science. 192: 1018-1020. PMID 1273584 DOI: 10.1126/Science.1273584  0.277
1997 Isacson O, Breakefield XO. Benefits and risks of hosting animal cells in the human brain. Nature Medicine. 3: 964-9. PMID 9288721 DOI: 10.1038/nm0997-964  0.277
1974 Lloyd T, Breakefield XO. Tyrosine-dependent increase of tyrosine hydroxylase in neuroblastoma cells Nature. 252: 719-720. PMID 4155049 DOI: 10.1038/252719a0  0.277
1994 Boviatsis EJ, Park JS, Sena-Esteves M, Kramm CM, Chase M, Efird JT, Wei MX, Breakefield XO, Chiocca EA. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Research. 54: 5745-51. PMID 7954393  0.276
2012 Kalra H, Simpson RJ, Ji H, Aikawa E, Altevogt P, Askenase P, Bond VC, Borràs FE, Breakefield X, Budnik V, Buzas E, Camussi G, Clayton A, Cocucci E, Falcon-Perez JM, et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. Plos Biology. 10: e1001450. PMID 23271954 DOI: 10.1371/Journal.Pbio.1001450  0.276
2018 Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, Ayre DC, Bach JM, Bachurski D, Baharvand H, Balaj L, ... ... Breakefield X, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles. 7: 1535750. PMID 30637094 DOI: 10.1080/20013078.2018.1535750  0.276
1995 Wei MX, Tamiya T, Rhee RJ, Breakefield XO, Chiocca EA. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 1: 1171-7. PMID 9815909  0.276
2000 Wang Y, Fraefel C, Protasi F, Moore RA, Fessenden JD, Pessah IN, DiFrancesco A, Breakefield X, Allen PD. HSV-1 amplicon vectors are a highly efficient gene delivery system for skeletal muscle myoblasts and myotubes. American Journal of Physiology. Cell Physiology. 278: C619-26. PMID 10712251 DOI: 10.1152/Ajpcell.2000.278.3.C619  0.276
1991 Murphy DL, Sims KB, Karoum F, Garrick NA, de la Chapelle A, Sankila EM, Norio R, Breakefield XO. Plasma amine oxidase activities in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase. Journal of Neural Transmission. General Section. 83: 1-12. PMID 2018626 DOI: 10.1007/Bf01244447  0.276
1978 Edelstein SB, Castiglione CM, Breakefield XO. Monoamine oxidase activity in normal and Lesch-Nyhan fibroblasts. Journal of Neurochemistry. 31: 1247-1254. PMID 702170 DOI: 10.1111/J.1471-4159.1978.Tb06249.X  0.276
2004 Bagley J, Cortes ML, Breakefield XO, Iacomini J. Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice. Blood. 104: 572-8. PMID 15044255 DOI: 10.1182/blood-2003-12-4226  0.275
1994 Bressman SB, de Leon D, Kramer PL, Ozelius LJ, Brin MF, Greene PE, Fahn S, Breakefield XO, Risch NJ. Dystonia in Ashkenazi Jews: clinical characterization of a founder mutation. Annals of Neurology. 36: 771-7. PMID 7979224 DOI: 10.1002/ana.410360514  0.275
2017 Figueroa JM, Skog J, Akers J, Li H, Komotar R, Jensen R, Ringel F, Yang I, Kalkanis S, Thompson R, LoGuidice L, Berghoff E, Parsa A, Liau L, Curry W, ... ... Breakefield X, et al. Detection of wtEGFR Amplification and EGFRvIII Mutation in CSF-Derived Extracellular Vesicles of Glioblastoma Patients. Neuro-Oncology. PMID 28453784 DOI: 10.1093/Neuonc/Nox085  0.274
1983 Cawthon RM, Breakefield XO. Differences in the structures of monoamine oxidases A and B in rat clonal cell lines Biochemical Pharmacology. 32: 441-448. PMID 6847697 DOI: 10.1016/0006-2952(83)90521-X  0.274
2004 Naismith TV, Heuser JE, Breakefield XO, Hanson PI. TorsinA in the nuclear envelope. Proceedings of the National Academy of Sciences of the United States of America. 101: 7612-7. PMID 15136718 DOI: 10.1073/Pnas.0308760101  0.273
1976 Roth JA, Breakefield XO, Castiglione CM. Monoamine oxidase and catechol-O-methyltransferase activities in cultured human skin fibroblasts. Life Sciences. 19: 1705-1710. PMID 1004130 DOI: 10.1016/0024-3205(76)90077-1  0.273
1980 Giller EL, Young JG, Breakefield XO, Carbonari C, Braverman M, Cohen DJ. Monoamine oxidase and catechol-O-methyltransferase activities in cultured fibroblasts and blood cells from children with autism and the Gilles de la Tourette syndrome. Psychiatry Research. 2: 187-97. PMID 6932062 DOI: 10.1016/0165-1781(80)90076-1  0.273
1992 Konradi C, Ozelius L, Breakefield XO. Highly polymorphic (GT)n repeat sequence in intron II of the human MAOB gene. Genomics. 12: 176-7. PMID 1733859 DOI: 10.1016/0888-7543(92)90426-S  0.273
2019 Zaborowski MP, Cheah PS, Zhang X, Bushko I, Lee K, Sammarco A, Zappulli V, Maas SLN, Allen RM, Rumde P, György B, Aufiero M, Schweiger MW, Lai CP, Weissleder R, ... ... Breakefield XO, et al. Membrane-bound Gaussia luciferase as a tool to track shedding of membrane proteins from the surface of extracellular vesicles. Scientific Reports. 9: 17387. PMID 31758005 DOI: 10.1038/S41598-019-53554-Y  0.273
1982 Levitt P, Pintar JE, Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proceedings of the National Academy of Sciences of the United States of America. 79: 6385-9. PMID 6755469 DOI: 10.1073/Pnas.79.20.6385  0.273
1998 Schellingerhout D, Bogdanov A, Marecos E, Spear M, Breakefield X, Weissleder R. Mapping the in vivo distribution of herpes simplex virions. Human Gene Therapy. 9: 1543-9. PMID 9694153 DOI: 10.1089/Hum.1998.9.11-1543  0.272
1999 Blumenfeld A, Slaugenhaupt SA, Liebert CB, Temper V, Maayan C, Gill S, Lucente DE, Idelson M, MacCormack K, Monahan MA, Mull J, Leyne M, Mendillo M, Schiripo T, Mishori E, ... Breakefield X, et al. Precise genetic mapping and haplotype analysis of the familial dysautonomia gene on human chromosome 9q31. American Journal of Human Genetics. 64: 1110-8. PMID 10090896 DOI: 10.1086/302339  0.272
2000 Bearer EL, Breakefield XO, Schuback D, Reese TS, LaVail JH. Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument. Proceedings of the National Academy of Sciences of the United States of America. 97: 8146-50. PMID 10884436 DOI: 10.1073/Pnas.97.14.8146  0.271
1979 Cawthon RM, Breakefield XO. Differences in A and B forms of monoamine oxidase revealed by limited proteolysis and peptide mapping Nature. 281: 692-694. PMID 551289 DOI: 10.1038/281692A0  0.27
2011 Deliolanis NC, Wurdinger T, Pike L, Tannous BA, Breakefield XO, Weissleder R, Ntziachristos V. In vivo tomographic imaging of red-shifted fluorescent proteins. Biomedical Optics Express. 2: 887-900. PMID 21483611 DOI: 10.1364/Boe.2.000887  0.269
2014 Redzic JS, Balaj L, van der Vos KE, Breakefield XO. Extracellular RNA mediates and marks cancer progression. Seminars in Cancer Biology. 28: 14-23. PMID 24783980 DOI: 10.1016/J.Semcancer.2014.04.010  0.269
1999 Bearer EL, Schlief ML, Breakefield XO, Schuback DE, Reese TS, LaVail JH. Squid axoplasm supports the retrograde axonal transport of herpes simplex virus. The Biological Bulletin. 197: 257-8. PMID 10573844 DOI: 10.2307/1542637  0.269
1986 Edelstein SB, Breakefield XO. Monoamine oxidases A and B are differentially regulated by glucocorticoids and "aging" in human skin fibroblasts. Cellular and Molecular Neurobiology. 6: 121-150. PMID 3731213 DOI: 10.1007/Bf00711066  0.269
1992 Gasser T, Fahn S, Breakefield XO. The autosomal dominant dystonias. Brain Pathology (Zurich, Switzerland). 2: 297-308. PMID 1341964 DOI: 10.1111/J.1750-3639.1992.Tb00707.X  0.268
1978 Crooks PA, Breakefield XO, Sulens CH, Castiglione CM, Coward JK. Extensive conjugation of dopamine (3,4-dihydroxyphenethylamine) metabolites in cultured human skin fibroblasts and rat hepatoma cells. The Biochemical Journal. 176: 187-96. PMID 569477 DOI: 10.1042/Bj1760187  0.268
1997 Kaye EM, Shalish C, Livermore J, Taylor HA, Stevenson RE, Breakefield XO. beta-Galactosidase gene mutations in patients with slowly progressive GM1 gangliosidosis. Journal of Child Neurology. 12: 242-7. PMID 9203065 DOI: 10.1177/088307389701200404  0.267
2008 Würdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, Weissleder R, Breakefield XO, Krichevsky AM. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell. 14: 382-93. PMID 18977327 DOI: 10.1016/J.Ccr.2008.10.005  0.267
1993 Takamiya Y, Short MP, Moolten FL, Fleet C, Mineta T, Breakefield XO, Martuza RL. An experimental model of retrovirus gene therapy for malignant brain tumors. Journal of Neurosurgery. 79: 104-10. PMID 8391069 DOI: 10.3171/jns.1993.79.1.0104  0.267
1980 Costa MRC, Edelstein SB, Castiglione CM, Chao H, Breakefield XO. Properties of monoamine oxidase in control and Lesch-Nyhan fibroblasts. Biochemical Genetics. 18: 577-590. PMID 7437013 DOI: 10.1007/Bf00484403  0.266
2011 Saydam O, Senol O, Würdinger T, Mizrak A, Ozdener GB, Stemmer-Rachamimov AO, Yi M, Stephens RM, Krichevsky AM, Saydam N, Brenner GJ, Breakefield XO. miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Research. 71: 852-61. PMID 21156648 DOI: 10.1158/0008-5472.Can-10-1219  0.265
1999 Klein C, Vieregge P, Hagenah J, Sieberer M, Doyle E, Jacobs H, Gasser T, Breakefield XO, Risch NJ, Ozelius LJ. Search for the PARK3 founder haplotype in a large cohort of patients with Parkinson's disease from northern Germany. Annals of Human Genetics. 63: 285-91. PMID 10738540 DOI: 10.1046/j.1469-1809.1999.6340285.x  0.264
2018 Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New Technologies for Analysis of Extracellular Vesicles. Chemical Reviews. PMID 29384376 DOI: 10.1021/Acs.Chemrev.7B00534  0.264
1984 Rosenberg MB, Grossman MH, Breakefield XO. Artifactual presence of β-nerve growth factor in adult mouse brain Brain Research. 295: 35-40. PMID 6713177 DOI: 10.1016/0006-8993(84)90813-8  0.264
2000 Klein C, Gurvich N, Sena-Esteves M, Bressman S, Brin MF, Ebersole BJ, Fink S, Forsgren L, Friedman J, Grimes D, Holmgren G, Kyllerman M, Lang AE, de Leon D, Leung J, ... ... Breakefield XO, et al. Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. Annals of Neurology. 47: 369-73. PMID 10716258 DOI: 10.1002/1531-8249(200003)47:3<369::Aid-Ana14>3.0.Co;2-9  0.264
1992 Girmen AS, Baenziger J, Hotamisligil GS, Konradi C, Shalish C, Sullivan JL, Breakefield XO. Relationship between platelet monoamine oxidase B activity and alleles at the MAOB locus. Journal of Neurochemistry. 59: 2063-6. PMID 1431894 DOI: 10.1111/J.1471-4159.1992.Tb10095.X  0.263
1983 Pintar JE, Maxwell GD, Breakefield XO. Characterization of monoamine oxidase activity during early stages of quail embryogenesis. International Journal of Developmental Neuroscience : the Official Journal of the International Society For Developmental Neuroscience. 1: 49-57. PMID 24875606 DOI: 10.1016/0736-5748(83)90010-2  0.263
1988 Hsu YP, Weyler W, Chen S, Sims KB, Rinehart WB, Utterback MC, Powell JF, Breakefield XO. Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences. Journal of Neurochemistry. 51: 1321-4. PMID 3418353 DOI: 10.1111/j.1471-4159.1988.tb03105.x  0.263
2003 Simon DK, Friedman J, Breakefield XO, Jankovic J, Brin MF, Provias J, Bressman SB, Charness ME, Tarsy D, Johns DR, Tarnopolsky MA. A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. Neurogenetics. 4: 199-205. PMID 12756609 DOI: 10.1007/s10048-003-0150-3  0.262
2000 McIvor RS, Ando D, Breakefield XO, Buckley R, Chow L, Deisseroth A, Greenblatt J, Mickelson C. Prenatal gene transfer: Scientific, medical, and ethical issues: A report of the recombinant DNA advisory committee Human Gene Therapy. 11: 1211-1229. PMID 11660775 DOI: 10.1089/10430340050015257  0.262
1994 Corey DP, Breakefield XO. Transcription factors in inner ear development. Proceedings of the National Academy of Sciences of the United States of America. 91: 433-6. PMID 8290543 DOI: 10.1073/Pnas.91.2.433  0.262
1995 Holmgren G, Ozelius L, Forsgren L, Almay BG, Holmberg M, Kramer P, Fahn S, Breakefield XO. Adult onset idiopathic torsion dystonia is excluded from the DYT 1 region (9q34) in a Swedish family. Journal of Neurology, Neurosurgery, and Psychiatry. 59: 178-81. PMID 7629534 DOI: 10.1136/Jnnp.59.2.178  0.261
2012 Bolukbasi MF, Mizrak A, Ozdener GB, Madlener S, Ströbel T, Erkan EP, Fan JB, Breakefield XO, Saydam O. miR-1289 and "Zipcode"-like Sequence Enrich mRNAs in Microvesicles. Molecular Therapy. Nucleic Acids. 1: e10. PMID 23344721 DOI: 10.1038/Mtna.2011.2  0.261
1980 Schwartz JP, Breakefield XO. Altered nerve growth factor in fibroblasts from patients with familial dysautonomia Proceedings of the National Academy of Sciences of the United States of America. 77: 1154-1158. PMID 6244581 DOI: 10.1073/Pnas.77.2.1154  0.261
2000 Bressman SB, Sabatti C, Raymond D, de Leon D, Klein C, Kramer PL, Brin MF, Fahn S, Breakefield X, Ozelius LJ, Risch NJ. The DYT1 phenotype and guidelines for diagnostic testing. Neurology. 54: 1746-52. PMID 10802779 DOI: 10.1212/Wnl.54.9.1746  0.26
2001 Sharma N, Hewett J, Ozelius LJ, Ramesh V, McLean PJ, Breakefield XO, Hyman BT. A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. The American Journal of Pathology. 159: 339-44. PMID 11438481 DOI: 10.1016/S0002-9440(10)61700-2  0.26
1989 Grossman MH, Creveling CR, Breakefield XO. Isolation of the mRNA encoding rat liver catechol-O-methyltransferase. Biochemical and Biophysical Research Communications. 158: 776-82. PMID 2645868 DOI: 10.1016/0006-291X(89)92789-7  0.259
2011 Erkan EP, Breakefield XO, Saydam O. miRNA signature of schwannomas: possible role(s) of "tumor suppressor" miRNAs in benign tumors. Oncotarget. 2: 265-70. PMID 21454924 DOI: 10.18632/Oncotarget.251  0.259
2009 Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Molecular and Cellular Biology. 29: 5923-40. PMID 19703993 DOI: 10.1128/Mcb.00332-09  0.259
1992 Ozelius L, Schuback DE, Stefansson K, Slaugenhaupt S, Gusella JF, Breakefield XO. Dinucleotide repeat polymorphism for the hexabrachion gene (HXB) on chromosome 9q32-34. Human Molecular Genetics. 1: 141. PMID 1284469 DOI: 10.1093/Hmg/1.2.141-A  0.259
1981 Edelstein SB, Breakefield XO. Dexamethasone selectively increases monoamine oxidase type A in human skin fibroblasts. Biochemical and Biophysical Research Communications. 98: 836-843. PMID 7225122 DOI: 10.1016/0006-291X(81)91187-6  0.258
1989 Powell JF, Hsu YP, Weyler W, Chen SA, Salach J, Andrikopoulos K, Mallet J, Breakefield XO. The primary structure of bovine monoamine oxidase type A. Comparison with peptide sequences of bovine monoamine oxidase type B and other flavoenzymes. The Biochemical Journal. 259: 407-13. PMID 2719656 DOI: 10.1042/Bj2590407  0.256
1980 Breakefield XO, Giller EL, Nurnberger JI, Castiglione CM, Buchsbaum MS, Gershon ES. Monoamine oxidase type A in fibroblasts from patients with bipolar depressive illness. Psychiatry Research. 2: 307-14. PMID 6932070 DOI: 10.1016/0165-1781(80)90022-0  0.256
2013 Prabhakar S, Goto J, Zhang X, Sena-Esteves M, Bronson R, Brockmann J, Gianni D, Wojtkiewicz GR, Chen JW, Stemmer-Rachamimov A, Kwiatkowski DJ, Breakefield XO. Correction: Stochastic Model of Tsc1 Lesions in Mouse Brain Plos One. 8. DOI: 10.1371/Annotation/6A5B0A50-27E4-49Bc-B82A-9267Dd63Af53  0.256
1992 Andersen JK, Herrup K, Breakefield XO. Creation of transgenic mice that overexpress monoamine oxidase-B neuronally. Annals of the New York Academy of Sciences. 648: 241-3. PMID 1637050 DOI: 10.1111/j.1749-6632.1992.tb24544.x  0.255
2015 Laurent LC, Abdel-Mageed AB, Adelson PD, Arango J, Balaj L, Breakefield X, Carlson E, Carter BS, Cavaller BM, Chen CC, Cocucci E, Danielson K, Courtright A, Das S, Abd Elmageed ZY, et al. Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. Journal of Extracellular Vesicles. 4: 26533. PMID 26320937 DOI: 10.3402/Jev.V4.26533  0.255
1992 Mikati MA, Maguire H, Barlow CF, Ozelius L, Breakefield XO, Klauck SM, Korf B, O'Tuama SL, Dangond F. A syndrome of autosomal dominant alternating hemiplegia: clinical presentation mimicking intractable epilepsy; chromosomal studies; and physiologic investigations. Neurology. 42: 2251-7. PMID 1361034 DOI: 10.1212/WNL.42.12.2251  0.254
2005 Bahn E, Pfander T, Siegert S, Kramer M, Schulz-Schaeffer W, Hewett J, Breakefield X, Gärtner J, Rostasy K. TorsinA and B expression in the brain is detectable in human infants as young as four weeks old Neuropediatrics. 36: 3. DOI: 10.1055/S-2005-867988  0.254
2016 Lööv C, Scherzer CR, Hyman BT, Breakefield XO, Ingelsson M. α-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities. Cellular and Molecular Neurobiology. PMID 26993503 DOI: 10.1007/S10571-015-0317-0  0.253
1981 Riker DK, Roth RH, Breakefield XO. High-affinity [3H]choline accumulation in cultured human skin fibroblasts. Journal of Neurochemistry. 36: 746-52. PMID 6257859 DOI: 10.1111/J.1471-4159.1981.Tb01651.X  0.252
2012 Shao H, Chung J, Balaj L, Charest A, Bigner D, Carter B, Hochberg F, Breakefield X, Weissleder R, Lee H. 443 Protein Typing of Circulating Microvesicles Allows Real-time Monitoring of Glioblastoma Therapy European Journal of Cancer. 48: 137-138. DOI: 10.1016/S0959-8049(12)72241-4  0.252
1992 Ozelius LJ, Kwiatkowski DJ, Schuback DE, Breakefield XO, Wexler NS, Gusella JF, Haines JL. A genetic linkage map of human chromosome 9q. Genomics. 14: 715-20. PMID 1427899 DOI: 10.1016/S0888-7543(05)80173-9  0.252
2018 Eimer WA, Vijaya Kumar DK, Navalpur Shanmugam NK, Rodriguez AS, Mitchell T, Washicosky KJ, György B, Breakefield XO, Tanzi RE, Moir RD. Alzheimer's Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection. Neuron. 99: 56-63.e3. PMID 30001512 DOI: 10.1016/J.Neuron.2018.06.030  0.251
1999 Jansen G, Peters GJ, Pinedo HM, Priest DG, Assaraf YG, Aghi M, Kramm CM, Breakefield XO, Sirotnak FM. Re: Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo [2] Journal of the National Cancer Institute. 91: 2047-2050. PMID 10580033 DOI: 10.1093/Jnci/91.23.2047A  0.251
2010 Smits M, Mir SE, Nilsson J, Stoop Pvd, Niers A, Marquez V, Cloos J, Breakefield X, Krichevsky A, Noske D, Tannous B, Wurdinger T. Abstract B30: Regulation of angiogenesis by the VEGF/miR-101/EZH2 axis Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-B30  0.251
2018 Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud AB, Speranza MC, Nakashima H, Hayes JL, Lee K, Balaj L, Passaro C, Rooj AK, Krasemann S, Carter BS, Chen CC, Steed T, ... ... Breakefield XO, et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Science Advances. 4: eaar2766. PMID 29532035 DOI: 10.1126/Sciadv.Aar2766  0.251
2000 Klein C, Schilling K, Saunders-Pullman RJ, Garrels J, Breakefield XO, Brin MF, deLeon D, Doheny D, Fahn S, Fink JS, Forsgren L, Friedman J, Frucht S, Harris J, Holmgren G, et al. A major locus for myoclonus-dystonia maps to chromosome 7q in eight families. American Journal of Human Genetics. 67: 1314-9. PMID 11022010 DOI: 10.1016/S0002-9297(07)62961-9  0.25
1999 Aghi M, Kramm CM, Breakefield XO. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. Journal of the National Cancer Institute. 91: 1233-41. PMID 10413425  0.25
2015 Shao H, Chung J, Lee K, Balaj L, Min C, Carter BS, Hochberg FH, Breakefield XO, Lee H, Weissleder R. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nature Communications. 6: 6999. PMID 25959588 DOI: 10.1038/Ncomms7999  0.25
2018 Gustafsson G, Lööv C, Persson E, Lázaro DF, Takeda S, Bergström J, Erlandsson A, Sehlin D, Balaj L, György B, Hallbeck M, Outeiro TF, Breakefield XO, Hyman BT, Ingelsson M. Secretion and Uptake of α-Synuclein Via Extracellular Vesicles in Cultured Cells. Cellular and Molecular Neurobiology. PMID 30288631 DOI: 10.1007/S10571-018-0622-5  0.25
2019 Abels ER, Broekman MLD, Breakefield XO, Maas SLN. Glioma EVs Contribute to Immune Privilege in the Brain. Trends in Cancer. 5: 393-396. PMID 31311653 DOI: 10.1016/j.trecan.2019.05.006  0.25
1976 Breakefield XO, Giller EL. Neurotransmitter metabolism in cell culture. Biochemical Pharmacology. 25: 2337-2342. PMID 11805 DOI: 10.1016/0006-2952(76)90024-1  0.25
1995 Risch N, de Leon D, Ozelius L, Kramer P, Almasy L, Singer B, Fahn S, Breakefield X, Bressman S. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nature Genetics. 9: 152-9. PMID 7719342 DOI: 10.1038/Ng0295-152  0.25
1992 Titlow CC, Andersen JK, Trofatter JA, Breakefield XO. In vitro translation of proteins with terminal deletions by SP6 RNA polymerase-mediated transcription of PCR products. Pcr Methods and Applications. 2: 172-4. PMID 1282438 DOI: 10.1101/Gr.2.2.172  0.249
2016 Abels ER, Breakefield XO. Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake. Cellular and Molecular Neurobiology. PMID 27053351 DOI: 10.1007/s10571-016-0366-z  0.249
2002 McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K, Breakefield XO, Hyman BT. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. Journal of Neurochemistry. 83: 846-54. PMID 12421356 DOI: 10.1046/J.1471-4159.2002.01190.X  0.249
1992 Cunningham LA, Short MP, Breakefield XO, Hansen JT, Bohn MC. Genetically modified astrocytes secreting beta-nerve growth factor (β-NGF) support adrenal chromaffin cells grafted into the striatum Journal of Neural Transplantation and Plasticity. 3: 235. DOI: 10.1155/NP.1992.235  0.247
2011 Smits M, Mir SE, Nilsson RJ, van der Stoop PM, Niers JM, Marquez VE, Cloos J, Breakefield XO, Krichevsky AM, Noske DP, Tannous BA, Würdinger T. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. Plos One. 6: e16282. PMID 21297974 DOI: 10.1371/journal.pone.0016282  0.247
1981 Cawthon RM, Pintar JE, Haseltine FP, Breakefield XO. Differences in the structure of A and B forms of human monoamine oxidase. Journal of Neurochemistry. 37: 363-72. PMID 7264664 DOI: 10.1111/J.1471-4159.1981.Tb00464.X  0.246
1999 Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Research. 59: 3861-5. PMID 10463570  0.245
1977 Archer EG, Breakefield XO, Sharata MN. Transport of tyrosine, phenylalanine, tryptophan and glycine in neuroblastoma clones. Journal of Neurochemistry. 28: 127-35. PMID 833588 DOI: 10.1111/J.1471-4159.1977.Tb07718.X  0.244
1991 Breakefield XO, DeLuca NA. Herpes simplex virus for gene delivery to neurons. The New Biologist. 3: 203-18. PMID 1652278  0.244
2002 Pal PK, Leung J, Hedrich K, Samii A, Lieberman A, Nausieda PA, Calne DB, Breakefield XO, Klein C, Stoessl AJ. [18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 789-94. PMID 12210877 DOI: 10.1002/Mds.10133  0.242
2017 Ricklefs FL, Speranza MC, Hayes J, Balaj L, Breakefield XO, Bronisz A, Carter B, Freeman G, Lawler S, Chiocca EA. P06.07 Immune evasion mediated by PD-L1 on glioblastoma derived extracellular vesicles Neuro-Oncology. 19: iii50-iii50. DOI: 10.1093/Neuonc/Nox036.181  0.241
2019 Das S, Ansel KM, Bitzer M, Breakefield XO, Charest A, Galas DJ, Gerstein MB, Gupta M, Milosavljevic A, McManus MT, Patel T, Raffai RL, Rozowsky J, Roth ME, et al. The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. Cell. 177: 231-242. PMID 30951667 DOI: 10.1016/J.Cell.2019.03.023  0.241
2008 Jinnah H, Richter A, Mink JW, Caldwell GA, Caldwell KA, Gonzalez-Alegre P, Cookson MR, Breakefield XO, Delong MR, Hess EJ. Animal models for drug discovery in dystonia. Expert Opinion On Drug Discovery. 3: 83-97. PMID 23480141 DOI: 10.1517/17460441.3.1.83  0.24
1987 Breakefield XO, Cambi F. Molecular genetic insights into neurologic diseases. Annual Review of Neuroscience. 10: 535-94. PMID 3551764 DOI: 10.1146/ANNUREV.NE.10.030187.002535  0.24
1979 Bartfai T, Breakefield XO, Greengard P. Regulation of synthesis of guanosine 3':5'-cyclic monophosphate in neuroblastoma cells. The Biochemical Journal. 176: 119-27. PMID 31871 DOI: 10.1042/bj1760119  0.239
2019 Srinivasan S, Yeri A, Cheah PS, Chung A, Danielson K, De Hoff P, Filant J, Laurent CD, Laurent LD, Magee R, Moeller C, Murthy VL, Nejad P, Paul A, Rigoutsos I, ... ... Breakefield XO, et al. Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation. Cell. 177: 446-462.e16. PMID 30951671 DOI: 10.1016/J.Cell.2019.03.024  0.239
1986 ROSENBERG MB, HAWROT E, BREAKEFIELD XO. Biotinylated β‐Nerve Growth Factor Binds to PC12 Cells Annals of the New York Academy of Sciences. 463: 214-216. DOI: 10.1111/J.1749-6632.1986.Tb21550.X  0.238
2007 Jeong KH, Bakowska JC, Song IO, Fu N, Breakefield XO, Kaiser UB. Improvement in reproductive parameters in hypogonadal female mice by regulated gene replacement therapy in the central nervous system. Gene Therapy. 14: 1092-101. PMID 17476303 DOI: 10.1038/sj.gt.3302957  0.238
1985 Rosenberg MB, Hansen C, Breakefield XO. Molecular genetic approaches to neurologic and psychiatric diseases. Progress in Neurobiology. 24: 95-140. PMID 3898226 DOI: 10.1016/0301-0082(85)90008-5  0.238
1985 Grossman MH, Creveling CR, Rybczynski R, Braverman M, Isersky C, Breakefield XO. Soluble and particulate forms of rat catechol-O-methyltransferase distinguished by gel electrophoresis and immune fixation. Journal of Neurochemistry. 44: 421-32. PMID 3880804 DOI: 10.1111/J.1471-4159.1985.Tb05432.X  0.238
1996 Yu JS, Sena-Esteves M, Paulus W, Breakefield XO, Reeves SA. Retroviral delivery and tetracycline-dependent expression of IL-1beta-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. Cancer Research. 56: 5423-7. PMID 8968096  0.237
2003 Saeki Y, Breakefield XO, Chiocca EA. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods in Molecular Medicine. 76: 51-60. PMID 12526158 DOI: 10.1385/1-59259-304-6:51  0.236
2006 Tannous BA, Grimm J, Perry K, Weissleder R, Breakefield XO. Metabolic biotinylation of mammalian cell receptors for imaging Nature Protocols. DOI: 10.1038/Nprot.2006.132  0.235
1986 Rosenberg MB, Hawrot E, Breakefield XO. Receptor Binding Activities of Biotinylated Derivatives of β‐Nerve Growth Factor Journal of Neurochemistry. 46: 641-648. PMID 3001230 DOI: 10.1111/J.1471-4159.1986.Tb13015.X  0.234
1995 Pechan PA, Yoshida T, Panahian N, Moskowitz MA, Breakefield XO. Genetically modified fibroblasts producing NGF protect hippocampal neurons after ischemia in the rat. Neuroreport. 6: 669-72. PMID 7605924 DOI: 10.1097/00001756-199503000-00021  0.231
2006 Senn C, Fraefel C, Breakefield XO. HSV Amplicon Vectors for Gene Delivery to the Nervous System Gene Therapy of the Central Nervous System: From Bench to Bedside. 25-43. DOI: 10.1016/B978-012397632-1/50004-6  0.229
2013 Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle S, Kalinina J, Hua W, Kesari S, Mao Y, Breakefield XO, Hochberg FH, Van Meir EG, Carter BS, Chen CC. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. Plos One. 8: e78115. PMID 24205116 DOI: 10.1371/Journal.Pone.0078115  0.226
2012 Lötvall J, Rajendran L, Gho YS, Thery C, Wauben M, Raposo G, Sjöstrand M, Taylor D, Telemo E, Breakefield XO. The launch of Journal of Extracellular Vesicles (JEV), the official journal of the International Society for Extracellular Vesicles - about microvesicles, exosomes, ectosomes and other extracellular vesicles. Journal of Extracellular Vesicles. 1. PMID 24009885 DOI: 10.3402/jev.v1i0.18514  0.226
1991 Konradi C, Ozelius L, Yan W, Gusella JF, Breakefield XO. Dinucleotide repeat polymorphism (D16S285) on human chromosome 16. Nucleic Acids Research. 19: 5449. PMID 1923837 DOI: 10.1093/NAR/19.19.5449  0.225
2002 Augood SJ, Hollingsworth Z, Albers DS, Yang L, Leung JC, Muller B, Klein C, Breakefield XO, Standaert DG. Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study. Neurology. 59: 445-8. PMID 12177384 DOI: 10.1212/Wnl.59.3.445  0.225
1979 Study RE, Breakefield XO, Bartfai T, Greengard P. Voltage-sensitive calcium channels regulate guanosine 3',5'-cyclic monophosphate levels in neuroblastoma cells. Proceedings of the National Academy of Sciences of the United States of America. 75: 6295-9. PMID 216020 DOI: 10.1073/pnas.75.12.6295  0.225
2022 Breyne K, Ughetto S, Rufino-Ramos D, Mahjoum S, Grandell EA, de Almeida LP, Breakefield XO. Exogenous loading of extracellular vesicles, virus-like particles, and lentiviral vectors with supercharged proteins. Communications Biology. 5: 485. PMID 35590035 DOI: 10.1038/s42003-022-03440-7  0.225
1989 Kwiatkowski DJ, Ozelius L, Schuback D, Gusella J, Breakefield XO. The gelsolin (GSN) cDNA clone, from 9q32-34, identifies BclI and StuI RFLPs. Nucleic Acids Research. 17: 4425. PMID 2567988 DOI: 10.1093/Nar/17.11.4425  0.223
2018 Dusoswa S, Verhoeff J, Abels E, Breakefield X, Noske D, Würdinger T, Broekman M, Kooyk YV, Garcia-Vallejo J. Tmic-28. Glioblastoma Exploits Cell Surface Glycosylation-Mediated Immune Regulatory Circuits For Immune Escape Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.1087  0.222
1992 Chen ZY, Hendriks RW, Jobling MA, Powell JF, Breakefield XO, Sims KB, Craig IW. Isolation and characterization of a candidate gene for Norrie disease. Nature Genetics. 1: 204-8. PMID 1303236 DOI: 10.1038/ng0692-204  0.222
2006 Tannous BA, Grimm J, Perry KF, Chen JW, Weissleder R, Breakefield XO. Erratum: Corrigendum: Metabolic biotinylation of cell surface receptors for in vivo imaging Nature Methods. 3: 657-657. DOI: 10.1038/Nmeth0806-657A  0.222
2020 van Solinge TS, Abels ER, van de Haar LL, Hanlon KS, Maas SLN, Schnoor R, de Vrij J, Breakefield XO, Broekman MLD. Versatile Role of Rab27a in Glioma: Effects on Release of Extracellular Vesicles, Cell Viability, and Tumor Progression. Frontiers in Molecular Biosciences. 7: 554649. PMID 33282910 DOI: 10.3389/fmolb.2020.554649  0.221
1989 Hsu YP, Powell JF, Sims KB, Breakefield XO. Molecular Genetics of the Monoamine Oxidases Journal of Neurochemistry. 53: 12-18. PMID 2656914 DOI: 10.1111/j.1471-4159.1989.tb07289.x  0.216
1986 Ozelius L, Mandel JL, Gusella JF, Breakefield XO. A new RFLP for D18S3(B74) an anonymous genomic clone localized to 18p113. Nucleic Acids Research. 14: 6782. PMID 3018684 DOI: 10.1093/NAR/14.16.6782-A  0.216
1998 Klein C, Vieregge P, Heide W, Kemper B, Hagedorn-Greiwe M, Hagenah J, Vollmer C, Breakefield XO, Kömpf D, Ozelius L. Exclusion of chromosome regions 6p12 and 15q11, but not chromosome region 7p11, in a German family with autosomal dominant congenital nystagmus. Genomics. 54: 176-7. PMID 9806847 DOI: 10.1006/geno.1998.5535  0.216
1991 Hotamisligil GS, Breakefield XO. Human monoamine oxidase A gene determines levels of enzyme activity. American Journal of Human Genetics. 49: 383-92. PMID 1678250  0.215
2017 Balaj L, Filant J, Nejad P, Paul A, Srinivasan S, Zhang X, Breakefield XO, Gandhi R, Laurent LC, Sood AK. Enrichment of extracellular vesicles using Millipore membrane filters followed by isolation of exosomal RNA from serum or plasma using the Qiagen miRNeasy Micro kit Protocol Exchange. DOI: 10.1038/Protex.2017.075  0.215
2022 Rufino-Ramos D, Lule S, Mahjoum S, Ughetto S, Cristopher Bragg D, Pereira de Almeida L, Breakefield XO, Breyne K. Using genetically modified extracellular vesicles as a non-invasive strategy to evaluate brain-specific cargo. Biomaterials. 281: 121366. PMID 35033904 DOI: 10.1016/j.biomaterials.2022.121366  0.212
1990 Schuback DE, Ozelius L, Hu G, Craft CM, Raese J, Breakefield XO, Hsu YPP. RFLP for human DBH (dopamine beta-hydroxylase) Nucleic Acids Research. 18: 387. PMID 1970168 DOI: 10.1093/nar/18.2.387-a  0.21
2022 O'Brien K, Ughetto S, Mahjoum S, Nair AV, Breakefield XO. Uptake, functionality, and re-release of extracellular vesicle-encapsulated cargo. Cell Reports. 39: 110651. PMID 35417683 DOI: 10.1016/j.celrep.2022.110651  0.209
1998 Rainov NG, Dobberstein KU, Heidecke V, Dorant U, Chase M, Kramm CM, Chiocca EA, Breakefield XO. Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector. Cancer Gene Therapy. 5: 158-62. PMID 9622099  0.208
1995 Risch N, DeLeon D, Fahn S, Bressman S, Ozelius L, Breakefield X, Kramer P, Almasy L, Singer B. Reply to “ITD in Ashkenazi Jews — genetic drift or selection?” Nature Genetics. 11: 14-15. DOI: 10.1038/Ng0995-14  0.206
2017 Balaj L, Paul A, Nejad P, Srinivasan S, Zhang X, Gandhi R, Laurent LC, Breakefield XO. Isolation of exosomal RNA from serum or plasma using ultracentrifugation and the Qiagen miRNeasy Micro kit Protocol Exchange. DOI: 10.1038/Protex.2017.079  0.206
2017 Balaj L, Filant J, Nejad P, Paul A, Simonson B, Srinivasan S, Zhang X, Breakefield XO, Das S, Gandhi R, Laurent LC, Sood AK. Isolation of exosomal RNA from serum or plasma using the Qiagen ExoRNeasy Midi kit Protocol Exchange. DOI: 10.1038/Protex.2017.073  0.206
2023 van Solinge TS, Friis KP, O'Brien K, Verschoor RL, van Aarle J, Koekman A, Breakefield XO, Vader P, Schiffelers R, Broekman M. Heparin interferes with the uptake of liposomes in glioma. International Journal of Pharmaceutics: X. 6: 100191. PMID 37408568 DOI: 10.1016/j.ijpx.2023.100191  0.205
2021 Prabhakar S, Lule S, DA Hora CC, Breakefield XO, Cheah PS. AAV9 transduction mediated by systemic delivery of vector via retro-orbital injection in newborn, neonatal and juvenile mice. Experimental Animals. PMID 34039790 DOI: 10.1538/expanim.20-0186  0.202
2002 Aguilar-Cordova CE, Macklin R, Markert ML, Mickelson CA, Ando DG, Breakefield XO, Friedmann TC, Gordon JW, Greenblatt JJ, Juengst ET, King NMP, Levi-Pearl SL. U.S. Department of Health and Human Services National Institutes of Health Recombinant DNA Advisory Committee: Minutes of meeting: December 6, 2001 Human Gene Therapy. 13: 1663-1673. DOI: 10.1089/10430340260201752  0.201
2008 Schubert M, Breakefield X, Federoff H, Frederickson RM, Lowenstein PR. Gene delivery to the nervous system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 640-6. PMID 18362921 DOI: 10.1038/mt.2008.42  0.201
1994 Shewach DS, Zerbe LK, Hughes TL, Roessler BJ, Breakefield XO, Davidson BL. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. Cancer Gene Therapy. 1: 107-12. PMID 7621241  0.199
2000 Estuardo Aguilar-Cordova C, Levi-Pearl SL, Macklin R, Markert ML, McIvor RS, Mickelson CA, Wolff JA, Ando DG, Breakefield XO, Chow LT, Friedmann T, Gordon JW, Greenblatt JJ, Juengst ET, King NMP. Department of health and human services national institutes of health recombinant DNA advisory committee: Minutes of meeting March 8-10, 2000 Human Gene Therapy. 11: 2159-2192. PMID 11044916 DOI: 10.1089/104303400750001453  0.199
2010 Nery F, Hora Cd, Caldwell K, Wang Q, Caldwell G, Tagaya M, Lencer W, Klein C, Ye Y, Breakefield X, Armata I, Farley J, Cho J, Yaqub U, Tannous B, et al. TorsinA participates in endoplasmic reticulum-associated degradation (ERAD) Nature Precedings. DOI: 10.1038/Npre.2010.4825  0.198
1991 Schuback DE, Ozelius L, Breakefield XO. BanI RFLP at AK1 locus (9q34). Nucleic Acids Research. 19: 5798. PMID 1682884 DOI: 10.1093/NAR/19.20.5798-A  0.196
2020 Nieland L, Morsett LM, Broekman MLD, Breakefield XO, Abels ER. Extracellular Vesicle-Mediated Bilateral Communication between Glioblastoma and Astrocytes. Trends in Neurosciences. PMID 33234347 DOI: 10.1016/j.tins.2020.10.014  0.196
2017 Balaj L, Filant J, Srinivasan S, Zhang X, Breakefield XO, Laurent LC, Sood AK. Exosome isolation from plasma using ExoQuick reagent Protocol Exchange. DOI: 10.1038/Protex.2017.071  0.195
2023 Lunavat TR, Nieland L, Vrijmoet AB, Zargani-Piccardi A, Samaha Y, Breyne K, Breakefield XO. Roles of extracellular vesicles in glioblastoma: foes, friends and informers. Frontiers in Oncology. 13: 1291177. PMID 38074665 DOI: 10.3389/fonc.2023.1291177  0.194
1997 Jacoby DR, Fraefel C, Breakefield XO. Hybrid vectors: a new generation of virus-based vectors designed to control the cellular fate of delivered genes. Gene Therapy. 4: 1281-3. PMID 9472550 DOI: 10.1038/sj.gt.3300578  0.194
1993 Chen ZY, Battinelli EM, Fielder A, Bundey S, Sims K, Breakefield XO, Craig IW. A mutation in the Norrie disease gene (NDP) associated with X-linked familial exudative vitreoretinopathy. Nature Genetics. 5: 180-3. PMID 8252044 DOI: 10.1038/ng1093-180  0.194
1994 Ozelius LJ, Breakefield XO. Co-factor insufficiency in dystonia-parkinsonian syndrome. Nature Genetics. 8: 207-9. PMID 7874157 DOI: 10.1038/ng1194-207  0.193
1997 Yu JS, Burwick JA, Dranoff G, Breakefield XO. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Human Gene Therapy. 8: 1065-72. PMID 9189764 DOI: 10.1089/hum.1997.8.9-1065  0.192
2009 Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. British Journal of Cancer. 100: 1603-7. PMID 19401683 DOI: 10.1038/sj.bjc.6605058  0.192
1995 Davar G, Bebrin WR, Day R, Breakefield XO. Gene delivery to mouse sensory neurons with herpes simplex virus: a model for postherpetic neuralgia and its treatment? Neurology. 45: S69. PMID 8545028 DOI: 10.1212/WNL.45.12_Suppl_8.S69  0.191
1995 Muldoon LL, Nilaver G, Kroll RA, Pagel MA, Breakefield XO, Chiocca EA, Davidson BL, Weissleder R, Neuwelt EA. Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. The American Journal of Pathology. 147: 1840-51. PMID 7495307  0.19
2021 Mahjoum S, Rufino-Ramos D, Pereira de Almeida L, Broekman MLD, Breakefield XO, van Solinge TS. Living Proof of Activity of Extracellular Vesicles in the Central Nervous System. International Journal of Molecular Sciences. 22. PMID 34298912 DOI: 10.3390/ijms22147294  0.189
2022 Lugani S, Halabi EA, Oh J, Kohler R, Peterson H, Breakefield XO, Chiocca EAA, Miller MA, Garris C, Weissleder R. Dual Immunostimulatory Pathway Agonism through a Synthetic Nanocarrier Triggers Robust Anti-Tumor Immunity in Murine Glioblastoma. Advanced Materials (Deerfield Beach, Fla.). e2208782. PMID 36427266 DOI: 10.1002/adma.202208782  0.189
1994 Davar G, Kramer MF, Garber D, Roca AL, Andersen JK, Bebrin W, Coen DM, Kosz-Vnenchak M, Knipe DM, Breakefield XO. Gene transfer to sensory neurons using herpes virus vectors. Gene Therapy. 1: S24. PMID 8542387  0.187
2023 Nieland L, Mahjoum S, Grandell E, Breyne K, Breakefield XO. Engineered EVs designed to target diseases of the CNS. Journal of Controlled Release : Official Journal of the Controlled Release Society. 356: 493-506. PMID 36907561 DOI: 10.1016/j.jconrel.2023.03.009  0.186
1997 Herrlinger U, Kramm CM, Johnston KM, Louis DN, Finkelstein D, Reznikoff G, Dranoff G, Breakefield XO, Yu JS. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Therapy. 4: 345-52. PMID 9408604  0.186
2008 Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biology. 10: 1470-6. PMID 19011622 DOI: 10.1038/ncb1800  0.185
2016 Ricklefs F, Mineo M, Rooj AK, Nakano I, Charest A, Weissleder R, Breakefield XO, Chiocca EA, Godlewski J, Bronisz A. Extracellular vesicles from high grade glioma exchange diverse pro-oncogenic signals that maintain intratumoral heterogeneity. Cancer Research. PMID 27013191 DOI: 10.1158/0008-5472.CAN-15-3432  0.184
2023 Rufino-Ramos D, Leandro K, Perdigão PRL, O'Brien K, Pinto MM, Santana MM, van Solinge TS, Mahjoum S, Breakefield XO, Breyne K, Pereira de Almeida L. Extracellular communication between brain cells through functional transfer of Cre mRNA mediated by extracellular vesicles. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 37194237 DOI: 10.1016/j.ymthe.2023.05.012  0.179
2023 Rufino-Ramos D, Leandro K, Perdigão PRL, O'Brien K, Pinto MM, Santana MM, van Solinge TS, Mahjoum S, Breakefield XO, Breyne K, de Almeida LP. Extracellular communication between brain cells through functional transfer of Cre mRNA. Biorxiv : the Preprint Server For Biology. PMID 36811091 DOI: 10.1101/2023.01.29.525937  0.177
1998 Bressman SB, de Leon D, Raymond D, Greene PE, Brin MF, Fahn S, Ozelius LJ, Breakefield XO, Kramer PL, Risch NJ. The role of the DYT1 gene in secondary dystonia. Advances in Neurology. 78: 107-15. PMID 9750907  0.175
1991 Kwiatkowski DJ, Ozelius L, Kramer PL, Perman S, Schuback DE, Gusella JF, Fahn S, Breakefield XO. Torsion dystonia genes in two populations confined to a small region on chromosome 9q32-34. American Journal of Human Genetics. 49: 366-71. PMID 1867195  0.169
1994 Cunningham LA, Short MP, Breakefield XO, Bohn MC. Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease. Brain Research. 658: 219-31. PMID 7834345  0.163
1993 Yan W, Boustany RM, Konradi C, Ozelius L, Lerner T, Trofatter JA, Julier C, Breakefield XO, Gusella JF, Haines JL. Localization of juvenile, but not late-infantile, neuronal ceroid lipofuscinosis on chromosome 16. American Journal of Human Genetics. 52: 89-95. PMID 8434611  0.158
Hide low-probability matches.